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Resumo 
 
 
Atualmente são comercializados em toda a união europeia medicamentos 
genéricos a um preço muito mais apelativo que os seus equivalentes de marca 
sendo este fator muitas vezes decisivo na escolha da marca do medicamento. 
No entanto, o facto da legislação referente aos genéricos estar atualmente 
facilitada em relação aos respetivos medicamentos de referência permite a 
produção de medicamentos genéricos com um custo mais baixo. Para isso, as 
farmacêuticas recorrem frequentemente a diferentes matérias primas e 
excipientes, por vezes, de menor qualidade que podem conter na sua matriz 
vários contaminantes considerados perigosos. Aliado a isto, existem ainda vários 
casos reportados sobre incidentes com medicamentos genéricos que 
apresentam diferentes efeitos secundários comparativamente aos seus 
medicamentos de referência, o que suscita muitas dúvidas e falta de confiança 
neste tipo de medicamentos tanto por parte dos profissionais de saúde como dos 
utentes. Com esta dissertação pretende-se adquirir conhecimento acerca da 
investigação já efetuada sobre esta temática, em específico, na quantificação de 
impurezas presentes em fármacos. Pretendeu-se também validar o método de 
quantificação de manganês, crómio e cobre em fármacos, bem como comparar 
impurezas presentes em medicamentos genéricos e nos respetivos 
medicamentos de referência. 
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Abstract 
 
Generic drugs are currently sold all over European union presenting a much 
more appealing price than their corresponding pharmaceutical drugs from other 
brands, which frequently influence the consumer regarding the choice of the 
drug brand. The lower prices are mostly due to the fact that the legislation 
applied to the generic drugs is currently simplified comparatively to the 
respective reference pharmaceutical drugs legislation, allowing that the 
pharmaceutical industry produce generic drugs at a lower cost. In order to 
reduce production costs even more, are often use different excipients and raw 
materials that sometimes present lower quality and may contain in their matrix 
several contaminants considered dangerous. In addition, there are several 
reported cases of incidents with generic drugs and generic pharmaceutical 
products with different side effects compared to their reference products, which 
raises many doubts and lack of trust in this type of pharmaceutical products both 
by health professionals and users. The aim of this dissertation is the 
acknowledgement of the studies published about the topic mentioned above, 
specifically, the determination and quantification of elemental impurities present 
in pharmaceutical drugs. It is also presented to validate the quantification 
method of manganese, chromium and cooper in pharmaceutical drugs, as well 
as, the determination and comparison of elemental impurities in both generic 
and respective reference pharmaceutical drugs. 
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1. PHARMACEUTICAL DRUGS 
Pharmaceutical drugs are economically considered to be a merit asset as in the various 
Member States of the European Union its widespread availability to the population is seen 
as a priority. About two-thirds of the expenditure in pharmaceutical drugs is assumed by the 
State itself and this primary role of the State in the widespread availability of medicines 
combined with the scientific progress that has diversified the supply of treatments and 
increased their effectiveness has been an effective determinant of improving living 
conditions and average longevity (Pereira and Vilares, 2014). 
The success achieved has led to a nominal growth of public expenses on pharmaceutical 
drugs substantially higher than the nominal growth of gross domestic product (GDP). Public 
expenses in the European Union Member States increased by an average of 76% between 
2000 and 2009, translating into an annual growth of 5.8%, against just a nominal gross 
domestic product growth of 2.8% (Vogler et al., 2011). 
Portugal is one of the Member States with the highest consumption of pharmaceutical 
drugs per capita and the tendency is to increase the numbers every year (Table 1).  
Table 1: Number of medicine packs sold and respective total values over the years in 
Portugal. 
Year 
Nº medicine 
packs 
Value at retail 
price (€) 
NHS charges 
(€) 
User charges 
(€) 
2013 149 086 465 1 849 703 511 1 160 219 375 689 484 136 
2014 153 020 413 1 873 043 848 1 170 352 630 702 691 219 
2015 154 964 976 1 891 956 858 1 182 180 185 709 776 673 
2016 155 972 138 1 887 107 629 1 189 820 191 697 287 438 
2017 157 349 517 1 913 105 122 1 213 514 100 699 591 022 
NHS – National Health Service 
As can be seen in Table 1, over the last 5 years the number of pharmaceutical drug packs 
has increased although the user charges are apparently decreasing. This is due to the fact that 
the NHS is increasingly participating more and in a higher proportion the pharmaceutical 
drugs that are more commonly used reducing the pharmaceutical charges weight to users 
(Infarmed, 2018). 
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According to the Portuguese Association of the Pharmaceutical Industry (Apifarma), 
since 1990 the use of pharmaceutical drugs has allowed that two billion years of healthy life 
was added to the Portuguese population. In other words, the use of pharmaceutical drugs 
prevented more than 110 thousand deaths in Portugal and contributed to the increase of up 
to 10 years in the average life expectancy of patients. 
The annual income of Portuguese families increased by 280 million euros due to the use 
of pharmaceutical drugs as the patients return to active life more quickly, and reduce the 
number of hospitalizations, ensuring savings to the health system (Apifarma, 2018). 
According to the Apifarma study (2018), the economic benefit of these years of healthy 
life is higher than the economic investment in the production of pharmaceutical drugs. 
However, this increase in pharmaceutical drugs consumption has negative implications too, 
as it is a heavy burden for the National Health Service and it also implies risks to the patient 
lives in the case of polimedication (simultaneous consumption of five or more 
pharmaceutical drugs) that can have extremely serious consequences for the patient and is 
responsible for many hospitalizations.  
Just in the first three months of 2018, the expenses of users with pharmaceutical drugs 
were 18,18 €/per capita and 48.2 % of the pharmaceutical’s units dispensed were generic. 
Table 2 shows the most consumed pharmaceutical drugs in the first three months of 2018 
(Silva and Santos, 2014). 
Table 2: Nº of pharmaceutical packs sold and market weigh of each of the most sold 
pharmaceutical drugs from January to March of 2018. 
Pharmacotherapeutic classification Nº of packs sold Market weigh 
Renin Angiotensin Axis Modifiers 3 284 702 8.1% 
Antidystopia 2 955 374 7.2% 
Anxiolytics, Sedatives and Hypnotics 2 646 239 6.5% 
Antidiabetics 2 403 361 5.9% 
Antidepressants 2 142 822 5.3% 
Anticoagulants 1 787 835 4.4% 
Gastric Secretion Modifiers 1 727 755 4.2% 
Adrenergic Activity Depressants 1 464 031 3.6% 
Analgesics and Antipyretics 1 392 312 3.4% 
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Antiepileptics and Anticonvulsants 1 084 863 2.7% 
Other Subgroups 19 901 666 48.8% 
Total 40 790 960 100% 
 
2. GENERIC PHARMACEUTICAL DRUGS 
A generic drug is a pharmaceutical product that has the same active substance, 
pharmaceutical form, and dosage as well as the same therapeutic indication as for the 
reference drug, a pharmaceutical drug that has already been authorised (EMA, 2012). 
According to Decree-Law no. 176/2006, of 30th of August, the MAH (Marketing 
Authorisation Holder) of generic pharmaceutical drugs is not subject to the same legal 
provisions of other pharmaceutical drugs, being the presentation of pre-clinical and clinical 
trials not required as long as the bioequivalence is demonstrated by bioavailability. When 
these studies are not appropriate, therapeutic equivalence by means of appropriate clinical 
pharmacology studies (tests strictly in accordance with the Community standards) or others 
to be requested by INFARMED can be applied. 
 
2.1. ADVANTAGES 
2.1.1. SAFETY AND EFFECTIVENESS 
European medicines agent (EMA) claims that as these pharmaceutical drugs have their 
active substances in the market for several years (10 years at least), they present a greater 
guarantee of effectiveness and allow a better knowledge of their safety profile. Therefore, 
European pharmaceutical drugs agent declares that through the bioavailability studies, 
generic drugs demonstrate their bioequivalence, being as safe and effective as the reference 
medicine but with a more appellative price for the user (Infarmed, 2016).  
 
2.1.2. COSTS 
In fact, generic pharmaceutical drugs are 20 to 35% cheaper than the reference 
pharmaceutical drugs with the same dosage and pharmaceutical form (Zarowitz, 2008), 
which considering our national economy, becomes an huge economic advantage for the users 
because these drugs are substantially cheaper than the reference pharmaceutical drugs. It is 
also an advantage for the NHS since it allows better management of available resources 
(Infarmed, 2016).  
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The lower cost of generic pharmaceutical drugs also has the potential to reduce the prices 
of their reference pharmaceutical products by creating a more competitive market because, 
as shown in some studies, generic pharmaceutical drugs do not present any inferiority 
relatively to their reference (Kesselheim et al., 2008). 
  
2.2. QUALITY 
Many generic pharmaceutical drugs are produced by the same manufacturer that already 
produced the respective reference pharmaceutical drugs when the patent of the reference 
ones expires. This ensures quality as it is the exact same product, however as the 
manufacturer just need to present bioequivalence tests, the pharmaceutical drugs price can 
be lowered (Peters et al., 2009). 
 That being said, one may think that generic pharmaceutical drugs are always 
undoubtedly the best choice, but it is not the case as they have some concerning 
disadvantages regarding testing and formulation (Lewek and Kardas, 2010). 
 
2.3. DISADVANTAGES 
 
2.3.1. BIOEQUIVALENCE 
As stated by the World Health Organization (WHO), for the bioequivalence study of a 
generic pharmaceutical drug it is only needed 18 to 24 healthy adult volunteers (WHO 
Technical Support Series, 1996). The people who are selected as volunteer can’t take 
medication or smoke at the time of the bioequivalence study. When an oral formulation is 
tested, the volunteers are also subject to a standardized meal to avoid the possibility of food 
coadministration interferences (US Food and Drug Administration, 2002). All of these 
precautions reduce the possibility of other interferences (like medication interference, 
current conditions and disease process) rather than by formulation ones. 
Moreover, to decrease and try to avoid even more the nondrug-related variations, in the 
studies of bioequivalence usually, it is applied a crossover design. In this study format, half 
of the volunteers receive the brand-name pharmaceutical drug first and then the test drug 
with a washout period in between, while the other half receive the pharmaceutical products 
in the reverse order.  Indeed, the study can be modified according to the drug that needed to 
be tested as is the case of extended release products and topical agents (Meyer, 1998). 
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The key point that is often questioned is whether all of these measures to minimize non-
drug related effects and variations mimic the real world. In fact, expert’s argument that these 
controlled environment does not represent at all the real world. They are worried that when 
generic products are taken by real patients that really have the illnesses, make use of other 
medications or have other medical conditions, the results may be dissimilar from the ones 
obtained in the equivalence studies in extremely controlled environments (Meredith, 2003). 
If this is the case, it may result in cancellation of the effect of the generic pharmaceutical 
drug or in more worrying cases, unwanted side effects that can greatly affect the patient's 
health.  
 
2.3.2. DIFFERENCES IN FORMULATION 
This is another disadvantage that is concerning the experts as it can affect the taking of 
generic pharmaceutical drugs by the patients. As already discussed, a generic pharmaceutical 
drug has to have exactly the same active ingredient as their reference in the same dose 
formulation and administrated by the same route of administration (Meredith, 2003). Non-
the-less, although the generic pharmaceutical drug has to have a similar ratio of inert to 
active compound as their reference, the inert ingredients, also called the excipient, does not 
have to be the same (Meredith, 2003). 
When there is a need for medicine taking in real life, usually the patient has to take 
several doses, however, the administration of the test drug in the bioequivalence tests is made 
in a single dose. Therefore, when the excipient in generic pharmaceutical drugs is different 
from the branded-drugs, critics wonder if, when taken for longer periods of time, the test 
drug serum concentration becomes too high or whether the excipient will affect any stage of 
the drug cycle like the absorption, distribution and metabolism (Lewek and Kardas, 2010). 
 
2.3.3. REPORTED INCIDENTS 
Taking generic pharmaceutical drugs instead of branded drugs for most medications 
usually poses no problem for the patients. However, in some drug classes, especially with 
narrow therapeutic range drugs the switch can be a problem as several cases of non-
bioequivalent generic drugs among others unexpected effects are reported (Lewek and 
Kardas, 2010).  
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Antiepileptic drugs are one example in which the several studies reported differences 
between generic and their reference pharmaceutical drug (Crawford et al., 2006). For 
instance, it was reported that 1 of 3 generic formulations of carbamazepine compared was 
not bioequivalent (Silpakit et al., 1997). Moreover, other 3 generic formulations of the same 
active compound were tested and although they were all bioequivalent, it was reported a 
faster absorption than the brand-name drug (Silpakit et al., 1997). 
Another example is the psychotropic agents in which there are reported cases of 
problems occurrence after the switch from one generic to another or from a reference 
pharmaceutical drug to the respective generic. Examples cited for the Food and Drug 
Administration (FDA) are amitriptyline/ perphenazine and venlafaxine (US Food and Drug 
Administration, 2018). 
There are also doubts about levothyroxine (LT4) administration and generic substitution 
as there are still reported cases of generic LT4 adverse results being the reported events 
mostly associated with the substitution of reference pharmaceutical drugs for generic ones 
and from one generic to another generic pharmaceutical drug (Hennessey et al., 2010).  
Overall, the safety, effectiveness, quality and mostly the significantly difference in retail 
price of generic pharmaceutical drugs and the huge advertising made for the use of generics 
appears to be overcoming all of the disadvantages associated with it, leading to a growing 
preference for generic pharmaceutical drugs rather than their reference ones as can be seen 
in the graphic presented by INFARMED in the monthly monitoring of drug consumption in 
the national health service outpatient clinic (Figure 1) (Infarmed, 2018). 
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Figure 1: Evolution of the sales of generic drugs over the years. DDD is a measuring 
unit assigned by the WHO (World Health Organization) that represents the average daily 
maintenance dose of a certain active substance in its main therapeutic indication for adults. 
A competitive market is the percentage of dispensed generic drugs. 
 
It is imperative to consider that this preference only highlights the importance of making 
sure that all generic pharmaceutical drugs are safe for usage. As the generic pharmaceutical 
drugs are often composed of different excipients it is extremely important to make sure that 
generic inert compounds have their elemental impurities under control. 
 
3. PHARMACEUTICAL DRUGS IMPURITIES 
Due to the fact that generic drugs have the whole process of obtaining the marketing 
authorisation holder simplified, they are exempt from the submission of expert reports on 
pharmacological, toxicological and clinical and preclinical tests according to the Decree-
Law no. 176/2006, of 30 August and this fact turns important to question the quality of the 
generic pharmaceutical drugs concerning inorganic impurities (Infarmed, 2018).  
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Pharmaceutical drug pills are composed by a blended powder containing active 
pharmaceutical ingredients called APIs and a matrix of inactive organic compounds called 
excipients that helps to stabilize and delivery successfully the APIs (St-Onge et al., 2002). 
Excipients are substances that don’t have therapeutic effects and are part of the 
pharmaceutical drugs to ensure their stability, physicochemical and organoleptic properties 
(Balbani et al., 2006; da Silva et al., 2017). 
The film coating of capsules and tablets can also offer physiological advantages as they 
reduce the irritation that the exposure of the stomach to the high concentration of 
pharmaceutical drugs often present (Romero-Torres et al., 2006). These film coatings are 
mostly composed of plasticizers, pigments or cellulosic and acrylic polymers since they 
present good film coating properties (Sakata et al., 2006). And therefore, titanium dioxide 
and iron oxide are widely used for this type of coating (Luo et al., 2008). 
As these types of elements, as well as others are part of the constitution of medicines, is 
imperative the determination of the impurities present in these pharmaceutical drugs because 
it is needed to ensure that all the impurities concentrations are below the legal maximum 
allowed. This is due to the fact that some elements in trace or even ultra-trace concentrations 
are toxic or can decrease the stability of active pharmaceutical ingredient.  
There are some elements that are considered toxic in any concentration as is the case of 
cadmium (Cd), mercury (Hg) and lead (Pb) although their level of toxicity depends on the 
chemical form. Other concerning element is arsenic (As) that, however, it is not as toxic as 
the above mentioned, in concentrations higher than the allowed may have harmful 
consequences on human health (Balaram, 2016; Fliszar et al., n.d.; ICH Expert Working 
Group, 2014). Both arsenic and cadmium are considered by the International Agency for 
Research on Cancer (IARC) as carcinogenic in their inorganic forms and although mercury 
can’t be considered carcinogenic (as it has low oral bioavailability), it can cause 
toxicological and hematopoietic effects, causing renal disorders and skin diseases (IARC 
Working Group on the Evaluation of Carcinogenic Risks to Humans, 2012). Lead, similar 
to mercury, cannot be considered carcinogenic but it causes neurological, reproductive, 
immune, cardiovascular and renal systems pathologies (ICH Expert Working Group, 2014). 
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Some inorganic impurities could also be indicators of non-adequate handling and storage 
(Zachariadis and Sahanidou, 2011) as many metallic ions besides putting at risk the human 
health security, also decreases the drug efficiency through the formation of stable metal-drug 
complexes (Incledon et al., 2003; Luo et al., 2008), or (under specific conditions) catalyse 
the degradation of the antibiotics (Romero-Torres et al., 2006; Sakata et al., 2006).  
Commercial antibiotics usually contain APIs and several excipients (organic and 
inorganic matrixes) and therefore, residues of metals in trace amounts are not likely to be 
found. However, when catalysts are used during synthetic processes the pharmaceutical drug 
must be tested for the catalyst used (Circus et al., 2002). In other words, if a specific metal 
is used as a catalyst in the synthetic processes, there is a chance that it led to the presence of 
residues of this metal in the final product and a specific element assay should be executed to 
determine the concentration of these residues. The presence of trace impurities in the final 
product can also occur when natural substances are used or when various excipients, diluting 
agents, natural flavours and others are included without proper purification, or by drugs 
interaction with equipment, containers and surfaces (during processing) (Balaram, 2016; 
Fliszar et al., n.d.; Resano et al., 2015; Stoving et al., 2013). 
As seen, most of the inorganic impurities found in trace or ultra-trace amounts can 
present toxicological risks and put human health at risk, being the effects of which very 
difficult to detect sometimes. Thus, there is a growing concern about monitoring the 
inorganic impurities, especially trace and ultra-trace elements that are of paramount 
importance. National and international legislation establish element specific daily exposures 
(PDEs) limits for finished pharmaceutical drug products as well as control standards and 
determination processes of these chemical elements, including analytical procedures and 
method validations.  
As in pharmaceutical drugs, the inorganic impurities can be present in the final product 
by a numerous of sources and stages of the process of manufacturing (APIs, excipients, raw 
material, etc), not all of the 24-potential concerning elemental impurities considered have to 
be tested. In fact, depending on the route of administration (oral, parenteral or inhalation) 
different classes of elemental impurities need to be tested (Menoutis et al., 2018). 
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The International Conference on Harmonization (ICH) developed a global policy for 
limiting impurities in pharmaceutical drugs and ingredients back in 2009 and implemented 
an explicit guidance on specification limits for elemental impurities worldwide. This 
“Guidelines for Element Impurities” considered four different classes of elemental 
impurities and their permitted daily exposure as shown in Table 3. 
Table 3: Element impurity permitted daily exposures depending on the route of 
administration and respective classes of elemental impurities. 
Element Class 
Oral PDE 
(µg/day) 
Parenteral 
PDE (µg/day) 
Inhalation PDE 
(µg/day) 
As 1 15 15 2 
Cd 1 5 2 2 
Hg 1 30 3 1 
Pb 1 5 5 5 
Co 2A 50 5 3 
V 2A 100 10 1 
Ni 2A 200 20 5 
Tl 2B 8 8 8 
Au 2B 100 100 1 
Pd 2B 100 10 1 
Ir 2B 100 10 1 
Os 2B 100 10 1 
Rb 2B 100 10 1 
Ru 2B 100 10 1 
Se 2B 150 80 130 
Ag 2B 150 10 7 
Pt 2B 100 10 1 
Li 3 550 250 25 
Sb 3 1200 90 20 
Ba 3 1400 700 300 
Mo 3 3000 1500 10 
Cu 3 3000 300 30 
Sn 3 6000 600 60 
Cr 3 11000 1100 3 
PDE – Permitted Daily Exposure 
 
Class 1 are all the impurities that are significantly toxic to humans and have limited or 
no use in the manufacturing of pharmaceutical drugs. Usually, these impurities come from 
raw materials and need evaluation on the risk assessment performed in all potential sources 
of elemental impurities and routes of administration. 
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Impurities considered Class 2 are in general toxic to humans depending on the route of 
administration and are divided into two sub-classes. Sub-class 2A are elements that present 
the probability of occurrence in the pharmaceutical drugs quite high and therefore need to 
be tested in the risk assessment for all potential sources of elemental impurities and routes 
of administration. On the other hand, in the sub-class 2B there are elemental impurities that 
present low probability of occurrence in the pharmaceutical drugs as they have low potential 
to be co-isolated with other materials and low abundance and thus, except if they are added 
intentionally during any manufacture process step of the pharmaceutical drug, does not exist 
the need to test these elemental impurities in the risk assessment. 
Class 3 elements are impurities that possess low oral administration toxicity but in the 
case of inhalation or parenteral administration route, they must entail a risk assessment. 
Lastly, elements like Al, B, Ca, Fe, K, Mg, Mn, Na, W, and Zn doesn’t present establish 
Permitted Daily Exposures (PDEs) in the document mentioned as their PDEs are different 
depending on regulations of each region due to their low toxicities. If these elemental 
impurities are present in pharmaceutical drugs, they must be addressed by the regional 
guidelines or regulations where these are going to enter the market (Pharma & Biopharma, 
2013).  
As seen, quality control is a crucial part of the manufacturing process of pharmaceutical 
drugs and therefore, the determination of potential impurities in the different stages of the 
manufacturing processes, especially in the final product, is obligatory.  
This need for quality control is even more highlighted in the case of pharmaceutical 
drugs prescribed  for continuous use, for example, in the treatment of chronic and/or 
degenerative diseases, for relieving pain, as contraceptives or even for the prevention of 
diseases as in these cases, the patient is permanently exposed to the elemental impurities 
present in the pharmaceutical drugs, that can be persistent and bioaccumulative in several 
human body parts (Figure 2). They may also generate unwanted and unknown 
pharmacological–toxicological effects (Balbani et al., 2006). 
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Figure 2: Pharmaceutical drug cycle - Medicines are taken orally pass through the liver 
before they are absorbed into the bloodstream. Other forms of drug administration bypass 
the liver, entering the blood directly. Retrieved from: 
https://publications.nigms.nih.gov/medbydesign/chapter1.html, accessed on 11/10/2018 
 
The control of these possible impurities is typically performed using limit tests, 
performed by several existent techniques. Although few studies have been published about 
elemental impurities quantification on pharmaceutical drug pills by Inductively Coupled 
Plasma-Mass Spectrometry (ICP-MS) or other existing techniques, a search has been made 
and the keywords mentioned next were used in Web of Science, SCOPUS and b-on:  
1. Elemental impurities 
2. ICP OR GF-AAS OR F-AAS 
3. Analysis OR quantification 
Few articles that contain the focus subject were found in the literature, nonetheless, the 
most relevant studies were presented in Table 4 mentioning all the conditions of the sample 
dissolution, treatment and analysis. 
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Table 4: Techniques used for the quantification of elemental impurities and respective conditions used as reported in the literature. 
Pharmaceutical 
Drug 
Type 
Dissolution and treatment 
method 
Sample 
weight 
Sample 
volume 
Analytical 
method 
Quantified 
parameters 
Obtained concentrations Ref. 
Amoxicillin Antibiotic 
Tablets were ground and sieved. 
<100 μm particle size fraction + 
0.5 mol/L HNO3 + Triton (0.5%, 
v/v) resulting in 200 µg/L slurry 
concentration. Stirring at 600 rpm 
and introduced during continuous 
stirring into the nebulization 
system using a peristaltic pump.  
(a) (a) ICP-AES 
7 elemental 
impurities 
(in µg/g) 
Al-n.d 
Ca-8.2 
Cu-n.d 
Fe-1.5 
Mg-94 
Mn-n.d 
Zn-0.81 
(Zachariad
is and 
Michos, 
2007) 
Arbidol 
(Umifenovir) 
Antiviral 
Microwave-assisted digestion in 
closed vessel: 100 mg of sample + 
6 mL HNO3 + 2 mL H2O2, 125 °C 
for 30 min. After cooling dilute 
with deionised water to 100 mL. 
100 mg 100 mL ICP-MS 
6 elemental 
impurities 
(in μg/g) 
Mn-0.96 
Co-0.94 
Ni-0.99 
Cu-0.99 
Pb-0.91 
Cd-1.04 
(Rudovica 
et al., 
2014) 
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Aspirin 
Non-Steroidal 
Anti-Inflammatory  
Microwave-assisted digestion in 
closed vessel: 200 mg Aspirin + 
3.0 mL HNO3 + 1.0 mL H2O2 
reacts for 10 min. Add 4.0 mL 
HNO3 + 2.0 mL of HCl. 
Microwave heating program: 5 
min ramp to 210 ºC, hold 5 min; 3 
min ramp to 250 ºC, hold 6 min. 
After 20 min cooling, transfer to 
50 mL volumetric flask, add 
internal standard and was then 
added, with a final concentration 
of 50 ug L−1 in the sample when 
diluted to volume with 1% nitric 
acid. 
200 mg 50 mL ICP-MS 
17 
elemental 
impurities 
(in µg/L) 
Cd-1.91 
Pb-2.04 
As-5.36 
Hg-11.67 
Co-19.92 
V-40.20 
Ni-78.95 
Tl-3.18 
Au-40.55 
 
Pb-39.40 
Ir-40.97 
Os-93.52 
Rh-39.48 
Ru-39.48 
Se-56.72 
Ag-60.60 
Pt-39.95 
(Menoutis 
et al., 
2018) 
Calcium 
Folinate 
Adjuvant 
Chemotherapy 
0.1 g of tablet ashed at 550 °C for 
1–2 h in a quartz crucible. After 
cooling, add 1.0 mL of aqua regia. 
Heat and evaporated to dryness. 
Dissolved in 100 mL of 0.2 mol/L 
HNO3 containing 10 ng/mL of 
indium as an internal standard. 
100 mg 100 mL ICP-MS 
12 
elemental 
impurities 
(in μg/g) 
Be-<0.01 
V-0.36 
Mn-<0.01 
Co-<0.07 
Ni-<0.01 
Cu-1.03 
 
Zn-8.2 
Mo<-0.23 
Cd-<0.001 
Sn-<0.001 
Tl-<0.001 
Pb-0.13 
(Lásztity 
et al., 
2002) 
Carbamazepine Anticonvulsant 
Microwave-assisted digestion in 
closed vessel: 400 mg sample + 2 
mL water + 2 mL of HNO3 + 2mL 
HCl. Heating program: 85 °C for 8 
min; 5 min ramp to 130 °C; 5 min 
ramp to 200 °C, 30 min hold at 200 
°C. Transfer to a 20 mL volumetric 
flask and dilute with water. For 
ICP measurements dilute 1:10 with 
water. 
400 mg 20 mL 
ICP-OES 
and ICP-
MS 
17 
elemental 
impurities 
(in µg/g) 
Cd-<0.070 
Co-<0.035 
Ir-<0.002 
Mn-<0.064 
Mo-<0.055 
Ni-<0.092 
Pb-<0.050 
Pd-<0.078 
Pt-<0.001 
Ru-<0.009 
Rh-<0.001 
Sn-<0.180 
Sb-<0.050 
V-<0.050 
Cu-<1.0 
Fe-<2.0 
Zn-<0.5 
(Wollein 
et al., 
2015) 
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Diclofenac 
Non-Steroidal 
Anti-Inflammatory  
Treatment and dissolution 
identical to the Carbamazepine 
pharmaceutical drug. 
400 mg 20 mL 
ICP-OES 
and ICP-
MS 
17 
elemental 
impurities 
(in µg/g) 
Cd-<0.070 
Co-<0.035 
Ir-<0.002 
Mn-<0.064 
Mo-<0.055 
Ni-<0.092 
Pb-<0.050 
Pd-<0.078 
Pt-<0.001 
Ru-<0.009 
Rh-<0.001 
Sn-<0.180 
Sb-<0.050 
V-<0.050 
Cu-<1.0 
Fe-<2.0 
Zn-<0.5 
(Wollein 
et al., 
2015) 
Enalapril 
(Enalapril 
maleate) 
Antihypertensive 
Treatment and dissolution 
identical to the Titrace 
pharmaceutical drug. 
400 mg 25 mL ICP-MS 
3 elemental 
impurities 
(in ng/g) 
Pd - <0.9 
Pt - <4 
Rh -<5 
(Simitchie
v et al., 
2008) 
Fingolimod Immunomodulating 
Microwave-assisted digestion in 
closed vessel: 200 mg sample + 4 
mL of HNO3 + 0.2 mL of HClO₄. 
Digest at 250°C–260 °C for 45 
minutes in a high-pressure 
autoclave. After cooling add 0.1 
mL of IS and transfer to a 10 mL 
volumetric flask and dilute with 
water.  
200 mg 10 mL ICP-OES 
6 elemental 
impurities 
Cu + Fe + Ni + Pb + Pd 
+ Zn - < 5ppm 
(Correale 
et al., 
2014) 
Heparin-Na 
(Intravenous 
Drug) 
Anticoagulants 
Lyophilization of samples. 
Residues acid digested at high 
pressure and evaporated to small 
volumes. V complexed with 
cupferron at a pH of 2 and 
extracted three times. After 
evaporation of the organic layers, 
the residues were dissolved in 
formic acid. 
(a) (a) GF-AAS 
1 elemental 
impurity 
(in µg/L) 
V-4.9 
(Heinema
nn and 
Vogt, 
2000) 
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Isosulfan blue 
Lymphatic imaging 
agent 
UV photolysis assisted digestion: 
75 mg sample + 3 mL HNO3 reacts 
for 10 min. Then add 200 μL H2O2 
+ 2 mL water + UV irradiation 
at 85 ± 5 °C for 1 h. At every 10 
min add 0.1 mL H2O2 + 1 mL 
HNO3 during digestion until a 
maximum of 4 additions. Finally, 
dilute to 10 mL volumetric flask 
with water. 
75 mg 10 mL ICP-MS 
5 elemental 
impurities 
(in µg/g) 
Cr- 0.48 
Cd- 0.46 
Cu- 0.81 
Sn- 1.67 
Pb- 1.2 
(Dash et 
al., 2011) 
Levetiracetam Antiepileptic 
Microwave-assisted digestion in 
closed vessel: 1g sample + 15 mL 
HNO3 + 2 mL H2O2 at 250ºC until 
obtain a clear solution and a 
reduction of volume to 5 mL. Then 
ramp of 10 °C, hold at 250 °C for 
10 min. After cooling transfer to a 
25 mL volumetric flask and dilute 
with Millipore water. 
1 g 25 mL ICP-OES 
23 
elemental 
impurities 
(in ppm) 
Ag- <0.4 
Au- <0.4 
As- <0.4 
Bi- <0.4 
Cd- <0.4 
Cr- <0.4 
Cu- <0.4 
Fe- <0.4 
Hg- <0.4 
Ir- <0.4 
Mn- <0.4 
Mo- <0.4 
Ni- <0.4 
Os- <0.4 
Pb- <0.1 
Pd- <0.4 
Pt- <0.4 
Rh- <0.1 
Ru- <0.4 
Sb- <0.4 
Sn- <0.4 
V- <0.4 
Zn- <0.4 
(Dash et 
al., 2011) 
Levodopa Antiparkinsonian 
Dissolved in 0.2 mol/L HNO3 to 
obtain the final concentration of 
0.1%. 
100 mg 100 mL ICP-MS 
12 
elemental 
impurities 
(in μg/g) 
Be-<0.01 
V-0.47 
Mn-<0.01 
Co-<0.01 
Ni-<0.01 
Cu-<0.01 
 
Zn-1.5 
Mo-0.08 
Cd-<0.001 
Sn-0.27 
Tl-<0.01 
Pb-<0.01 
(Lásztity 
et al., 
2002) 
Lisinipril ACE Inhibitor 
Treatment and dissolution 
identical to the Aspirin one. 
200 mg 50 mL ICP-MS 
17 
elemental 
impurities 
(in µg/L) 
Cd-2.04 
Pb-2.00 
Au-41.27 
Pb-42.80 
Ir-40.62 
(Menoutis 
et al., 
2018) 
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As-6.34 
Hg-12.13 
Co-20.63 
V-40.75 
Ni-82.57 
Tl-3.22 
Os-112.28 
Rh-40.25 
Ru-41.27 
Se-65.55 
Ag-60.07 
Pt-41.05 
Metformin 
Hydrochloride 
Biguanide 
Hypoglycemic 
Agent 
Microwave-assisted digestion in 
triplicate closed vessel: 500 mg + 
5.0 mL inverse aqua regia. Heating 
program: 2 min ramp to 170 °C, 5 
min hold; 2 min ramp to 190 °C, 10 
min hold; 2 min ramp to 210 °C, 20 
min hold. After cooling dilute to 
50 mL volumetric flask with 
distilled-deionized water. When 
containing residual solids: 
centrifuged for 5 min at 3500 rpm. 
After, dilute 0.1 mg of the solution 
with deionized water. 
500 mg 50 mL ICP-MS 
4 elemental 
impurities 
(in µg/kg) 
As-99 
Cd-115 
Hg-87 
Pb-n.d 
 
(da Silva 
et al., 
2017) 
 
Methotrexate Anti-Rheumatics 
Microwave-assisted digestion:  
Into the quartz vessel: 200 mg 
Methotrexate + 1 mL concentrated 
H2SO4 + 0.5 mL concentrated 
HNO3. Outside quartz vessel: 3 
mL concentrated HNO3. 12 
samples were heated at the same 
time using a microwave program. 
After cooling continue digestion 
using another heating program. 
After, sample dilution with 
ultrapure water into 20 mL 
volumetric flasks. 
200 mg 20 mL GF-AAS 
2 elemental 
impurities 
(in μg/g) 
Fe- 0.41 
Pd-0.60 
(Niemelä 
et al., 
2004) 
20 
 
Naloxone Opioid antagonist 
Treatment and dissolution 
identical to the Carbamazepine 
pharmaceutical drug. 
400 mg 20 mL 
ICP-OES 
and ICP-
MS 
17 
elemental 
impurities 
(in µg/g) 
Cd-<0.070 
Co-<0.035 
Ir-<0.002 
Mn-<0.064 
Mo-<0.055 
Ni-<0.092 
Pb-<0.050 
Pd-<0.078 
Pt-<0.001 
Ru-<0.009 
Rh-<0.001 
Sn-<0.180 
Sb-<0.050 
V-<0.050 
Cu-<1.0 
Fe-<2.0 
Zn-<0.5 
(Wollein 
et al., 
2015) 
Paracetamol 
Analgesic and 
Antipyretic 
Microwave-assisted digestion in 
closed vessel: 400 mg Paracetamol 
+ 2 mL H2O + 1 mL HNO3 + 1 mL 
HCl. Heating program: 85 °C hold 
8 min; 5 min ramp to 130 °C; 5 min 
ramp to 200 °C, 30 min hold. After 
cooling add H2O to 20 mL volume. 
For ICP-MS measurements dilute 
solution to 1:10 with water. 
400 mg 20 mL 
ICP-MS 
and ICP-
OES 
21 
elemental 
impurities 
(in ppm) 
Mo-n.d 
Cu-n.d 
Cr-n.d 
Mn-0.25 
Fe-25 
Zn-n.d 
Co-n.d 
Ni-25 
Pb-0.10 
Cd-n.d 
As-n.d 
Hg-n.d 
Pd-n.d 
Pt-n.d 
Ir-n.d 
Os-n.d 
Ru-n.d 
V-0.11 
Sn-n.d 
Sb-n.d 
Rh-n.d 
(Wollein 
et al., 
2015) 
Ramipril 
(Tritace) 
Antihypertensive 
Microwave-assisted digestion in a 
closed vessel: 0.4 g of sample + 4 
mL HCl + 2 mL of H2O2, cooled 
down for 1 hour and digest 6 
vessels with a heating program. 
After, transfer and dilute to a 25 
mL volumetric flask and 
centrifuged for 15 min at 3000 
rpm. Heating program: 2 min at 
60% power, cooling for 5 min; 2 
min at 60% power, cooling for 5 
min; 2 min at 30% power, cooling 
400 mg 25 mL ICP-MS 
3 elemental 
impurities 
(in ng/g) 
Pd - <0.8 
Pt - 77 
Rh -<4 
(Simitchie
v et al., 
2008) 
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n.d - All results indicated by "n.d." show levels lower than Limit of Quantitation. 
(a) – Value not indicated in the correspondent pharmaceutical product literature. 
   
for 5 min; 2 min at 30% power, 
cooling for 30 min; 
Simvastatin Antilipemic Agent 
Microwave digestion: 3g 
simvastatin + 10 mL deionized 
water + 10 mL HNO3 + 2 mL H2O2 
and repeat 3 times. Then add 30mL 
HNO3 + 6 mL H2O2. Digest until 
left 3 mL. After cooling transfer to 
a 50 mL volumetric flask, dilute 
with ultra-pure water. Take 5 mL 
into 10 mL volumetric flask + 0.5 
mL HCl + 2 mL standard solution 
and dilute with ultra-pure water to 
the mark. 
 
3 g 50 mL AAS 
1 elemental 
impurity 
(in µg/mL) 
Li-<0.009 
(Jia Tao, 
Hao Qian, 
n.d.) 
Unknown Antibiotic 
Digestion: 
0.1 g of sample + HNO3 – HCl – 
HF solution + 2.00 mg L-1 of 
yttrium as internal standard. 
100 mg (a) 
ICP-OES 
and ICP-
MS 
10 
elemental 
impurities 
(in μg/g) 
Ti- 0.854 
Al- n.d 
Zn- n.d 
Mg- n.d 
Fe- n.d 
 
 
Cu- n.d 
Mn- n-d 
Cr- n.d 
Pb-n.d 
B-n.d 
(Zachariad
is and 
Sahanidou
, 2011) 
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The following factors were analysed based on the selected articles from the literature 
review presented above. 
 
3.1.  TYPE OF PHARMACEUTICAL PRODUCT 
The pharmaceutical drugs most analysed are from the most variate types and coincident 
with the utmost used type of pharmaceutical drugs. The range goes from simple Non-
Steroidal Anti-Inflammatory drug like Aspirin, Diclofenac (Menoutis et al., 2018) or 
Paracetamol (Wollein et al., 2015) that does not require a prescription, passing through the 
most consumed antibiotics like Amoxicillin (Zachariadis and Michos, 2007), anticoagulants 
(Heinemann and Vogt, 2000), anti-rheumatic like Methotrexate (Niemelä et al., 2004), 
biguanide hypoglycemic agent (da Silva et al., 2017), ACE inhibitor (Menoutis et al., 2018), 
antilipemic agent (Jia Tao, Hao Qian, n.d), antihypertensive (Simitchiev et al., 2008), 
antiepileptic (Dash et al., 2011), anticonvulsant (Wollein et al., 2015) or an antiviral drug 
(Rudovica et al., 2014) that already require a prescription. It was also reported the analysis 
of a more specific range of pharmaceutical drugs in which are included the antiparkinsonian 
Levodopa, chemotherapy adjuvants as is the case of Calcium Folinate (Lásztity et al., 2002), 
opioid antagonist (Wollein et al., 2015), lymphatic imaging agent (Dash et al., 2011) or an 
immunomodulating (Correale et al., 2014). 
 
3.2.  SAMPLE DISSOLUTION AND TREATMENT METHODS 
Sample preparation is a fundamental step in inorganic pharmaceutical impurities 
detection and quantification tests as they present low detection limits (< 1μg/g) and difficult 
matrices. In general, as seen in the Table 4, if the pharmaceutical drug is water-soluble or 
miscible liquid substance, it can be simply dissolved in suitable acids, solvents or solvent 
mixture as it is the case of levodopa that it is simply dissolved in HNO3 (Lásztity et al., 
2002).  
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However, if the matrix is difficult to dissolve, the sample has to be digested, using UV 
photolysis assisted digested, microwave-assisted digested or directly introduced in the spray 
chamber in the form of a slurry. The last two techniques have the advantage of low risk of 
contamination and the last one has an even greater advantage that eliminates the time-
consuming digestion step. There are two types of microwave digestion described in 
literature, wet sample digestion that it is the most common one and dry sample digestion that 
has been shown better results (Altundag and Tuzen, 2011). Nonetheless, concerning the 
determination and quantification of elemental impurities in pharmaceutical products, the 
only form of microwave-assisted digestion found in literature was wet digestion as shown in 
Table 4.  
In all of the pharmaceutical drugs that presented sample wet microwave-assisted 
digestion, the digestion was in almost all cases carried out using HNO3 in several 
concentrations (Correale et al., 2014; Dash et al., 2011; Jia Tao, n.d.; Menoutis et al., 2018; 
Niemelä et al., 2004; Rudovica et al., 2014; da Silva et al., 2017; Simitchiev et al., 2008; 
Wollein et al., 2015), H2O2 (Dash et al., 2011; Jia Tao, n.d.; Menoutis et al., 2018; Rudovica 
et al., 2014; Simitchiev et al., 2008), HCL (Jia Tao, n.d.; Menoutis et al., 2018; da Silva et 
al., 2017; Wollein et al., 2015) and H2O (Jia Tao, n.d.; Wollein et al., 2015).  
The digestion maximum temperatures varied between 125ºC (Rudovica et al., 2014) and 
550ºC (Lásztity et al., 2002) using several microwave heating programs to obtain the optimal 
digestion temperature.  
Regarding the direct introduction of the sample in the form of a slurry it was only used 
in the case of the antibiotic amoxicillin and the sample was diluted with HNO3 (Zachariadis 
and Michos, 2007). UV photolysis assisted digestion with HNO3, H2O2 and H2O was used 
in the case of Isosulfan Blue (Dash et al., 2011), simple digestion in the case of the unknown 
antibiotic and it was performed with a mixture of HNO3, HCl and HF (Zachariadis and 
Sahanidou, 2011). It was reported a lyophilization too for the sample treatment of Heparin-
Na (intravenous drug) (Heinemann and Vogt, 2000).  
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3.3.  SAMPLE WEIGHT 
The sample weight varies from 75 mg to 3 g depending on the pharmaceutical drug. For 
Isosulfan Blue the sample weight was 75 mg (Dash et al., 2011) while for Calcium Folinate, 
Levodopa, Arbidol and an unknown antibiotic the sample weight was 100 mg (Lásztity et 
al., 2002; Rudovica et al., 2014; Zachariadis and Sahanidou, 2011). In the case of Aspirin, 
Fingolimod, Lisinipril and Methotrexate the sample weight was 200 mg (Correale et al., 
2014; Menoutis et al., 2018; Niemelä et al., 2004), 400 mg for Paracetamol, Ramipril, 
Naloxone, Enalapril, Diclofenac and Carbamazepine (Simitchiev et al., 2008; Wollein et al., 
2015) and 500 mg for Metformin Hydrochloride samples (da Silva et al., 2017). Finally, 1g 
in the case of Levetiracetam samples (Dash et al., 2011) and for Simvastatin the sample 
weight was 3 g (Jia Tao, n.d.).  
For Amoxicillin and Heparin-Na, the sample weight is not known as the literature do 
not provide them (Heinemann and Vogt, 2000; Zachariadis and Michos, 2007). 
 
3.4.  SAMPLE VOLUME 
In all the cases, the sample volume varies from 10 mL to 100 mL which is a relatively 
low sample volume. For Isosulfan Blue and Fingolimod the sample volume was 10 mL 
(Correale et al., 2014; Dash et al., 2011) while for Paracetamol, Naloxone, Enalapril, 
Diclofenac, Carbamazepine and Methotrexate the volume used was 20 mL (Niemelä et al., 
2004; Simitchiev et al., 2008; Wollein et al., 2015). In the case of Ramipril and 
Levetiracetam the sample volume used was 25 mL (Dash et al., 2011; Simitchiev et al., 
2008), for Aspirin, Lisinipril, Simvastatin and Metformin Hydrochloride the sample volume 
used in literature was 50 mL (Jia Tao, n.d.; Menoutis et al., 2018; da Silva et al., 2017), while 
for Calcium Folinate, Levodopa and Arbidol the volume used was 100 mL (Lásztity et al., 
2002; Rudovica et al., 2014). 
Regarding the unknown antibiotic, Amoxicillin and Heparin-Na, the sample volume is 
not provided by the literature (Heinemann and Vogt, 2000; Zachariadis and Michos, 2007; 
Zachariadis and Sahanidou, 2011).  
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3.5.  ANALYTICAL METHOD 
The analytical methods found in the literature that reported elemental impurities in 
pharmaceutical formulations were both ICP-OES and ICP-MS for Paracetamol, Naloxone, 
Diclofenac, Carbamazepine, Metformin Hydrochloride and an unknown antibiotic (da Silva 
et al., 2017; Wollein et al., 2015; Zachariadis and Sahanidou, 2011). For Aspirin, Lisinipril, 
Calcium Folinate, Ramipril, Metformin Hydrochloride, Isosulfan Blue, Enalapril, Arbidol 
and Levodopa it was only reported the use of ICP-MS (Dash et al., 2011; Lásztity et al., 
2002; Menoutis et al., 2018; Rudovica et al., 2014; da Silva et al., 2017; Simitchiev et al., 
2008), while for Amoxicillin, Levetiracetam and Fingolimod was reported the exclusive use 
of ICP-OES (Correale et al., 2014; Dash et al., 2011; Zachariadis and Michos, 2007). 
Other older techniques were used as was the case of Simvastatin that used AAS (Jia Tao, 
n.d.) and Heparin-Na (Intravenous Drug) and Methotrexate that used GF-AAS (Heinemann 
and Vogt, 2000; Niemelä et al., 2004).  
 
3.6.  QUANTIFIED PARAMETERS AND OBTAINED CONCENTRATIONS 
In all cases, the parameters quantified were elemental impurities. These impurities were 
different depending on the pharmaceutical drug because as seen on CHAPTER I topic 
3.PHARMACEUTICAL IMPURITIES, not all of the 24-potential concerning elemental 
impurities considered have to be tested, as it depends on the route of administration, 
materials and reagents used in the several stages of the manufacturing stages.  
The obtained concentrations described in the literature were in most cases below the 
detection limit and therefore are presented as n.d or with a sign (<) followed by the 
quantification limit of the elemental impurity. The element concentration obtained were 
expressed in µg/L in the case of Aspirin, Lisinipril and Heparin-Na (Heinemann and Vogt, 
2000; Menoutis et al., 2018) and in µg/mL in the case of Simvastatin (Jia Tao, n.d.). For 
Paracetamol, Leveteracitam and Findolimod the concentrations were presented in ppm 
(Correale et al., 2014; Dash et al., 2011; Wollein et al., 2015) and for Metformin 
Hydrochloride in µg/kg (da Silva et al., 2017). In the case of Amoxicillin, Methotrexate, 
Calcium Folinate, Levodopa, Naloxone, Isosulfan Blue, Diclofenac, Carbamazepine, 
Arbidol and the unknown antibiotic the elemental concentrations were expressed in µg/g 
(Dash et al., 2011; Lásztity et al., 2002; Niemelä et al., 2004; Rudovica et al., 2014; Wollein 
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et al., 2015; Zachariadis and Michos, 2007; Zachariadis and Sahanidou, 2011). In addition, 
the results of Ramipril and Enalapril were presented in ng/g (Simitchiev et al., 2008). 
 
4. HYPOTHESIS OF WORK AND OBJECTIVES  
With the already said increasing tendency to consume generic pharmaceutical drugs 
instead of the reference medicine and according to the reported data on determination of 
elemental impurities on pharmaceutical drugs present on Table 4, the limited information in 
this area of study and the lack of literature comparing elemental impurities of generic drugs 
with their reference medicines using ICP are prominent. Therefore, the overall aim of this 
research is to develop and validate rapid and sensitive ICP methods for the determination of 
elemental impurities in generic pharmaceutical drugs and compare the results with their 
reference medicines. Specific objectives are: 
⎯ To successfully dissolve and treat pharmaceutical product samples based on the 
processes described in literature; 
⎯ To analyse and validate a methodology for pharmaceutical drugs by ICP-MS; 
⎯ To analyse, compare and evaluate major differences regarding elemental impurities 
both in generic and reference pharmaceutical drugs; 
Additionally, a proposed sample treatment and digestion method based on the literature 
found will be presented. 
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CHAPTER II: METHODS AND MATERIALS 
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1. SOLUTIONS AND REAGENTS 
It was used class 1 water for the material washing, and ultra-pure water for dilutions and 
preparation of all the standard solutions. The ultra-pure water was obtained using an ultra-
purification Helix system coupled with a Mili-Q filter, assuring a resistivity of 18,2 MΩ.cm 
and a total organic carbon concentration of approximately 1 μg/L. 
All the reagents used throughout the work had at least p.a. puriss. More in detail, it was 
used nitric acid with a puriss of at least 65% (v/v), hydrochloric acid fuming with 37% (v/v) 
and Perdrogen (hydrogen peroxide) with at least 30% (w/w) for the sample digestions and 
in the blank solution used for the instrument background. 
For the daily optimization of the ICP-MS equipment sensibility, it was used a solution 
with a 10 mg/L concentration, named Tune A, containing a matrix that matches to the one 
present in the samples. This match minimizes the matrix effects and corrects the background. 
As internal standard it was used a solution of Indium 115 with a concentration of 
approximately 23 µg/L. The washing solution used between different sample reading is a 
solution of 1% (v/v) of nitric acid. 
Given that there aren’t certified reference materials for pharmaceutical drugs, the 
quantification limit verification standard solutions could not be prepared (PVLQ). Therefore, 
it were only prepared the calibration curve verification standard solutions (PVRC).  
It is important to enhance that all the PVRC were prepared by dilution of a mother-
solution with an element concentration of 10 mg/L. This primary solution was also prepared 
using a multielement commercial solution. All the solutions were prepared and stored in 
plastic flasks. 
 
2. MATERIAL WASHING 
In the determination of elemental impurities, it is extremely important to prevent the 
contamination of the analyte. As it is a technique with high sensibility, the smallest add or 
loss of analyte will influence immensely the results obtained. Therefore, all the material has 
to be properly washed to prevent contamination of the analyte with dust in the laboratory 
environment or material impurities.  
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In order to accomplish the best washing, before each use, all the equipment used was 
washed with a solution of 96% (v/v) of ethanol and dried. The microwave Teflon vessels 
had a specific washing treatment, they were washed with the laboratory detergent, tap water 
and dried. Then, the Teflon vessels were submitted to a microwave washing program, 
specific for the vessels in use, with a solution of 50% (v/v) of nitric acid. Lastly, all the 
Teflon vessels were washed 10 times with ultrapure water (mili-Q water) and dried with 
compressed air.    
 
3. SAMPLE PREPARATION METHOD 
Giving the lack of certified reference material (CRM) regarding pharmaceutical 
products, there were only analysed standard and pharmaceutical drugs samples during the 
work. All the pharmaceutical samples were prepared following the same method, being each 
pharmaceutical drug, grounded in a mortar to homogenize the sample and then, all the 
samples were weight and microwaved-assisted digested.  In more detail, 6 pills of each 
pharmaceutical drug used were ground in a mortar and stored in a plastic test tube, then, 
weighted 200 mg of the pharmaceutical sample directly to a Teflon vessel. To minimize the 
static electricity that causes material dispersion, every Teflon vessel was coated with 
aluminium foil when weighing. It was then added to the Teflon vessel 1.5 mL of nitric acid, 
0.5 mL of hydrochloric acid and 0.1 mL of hydrogen peroxide. This process was repeated 
for each pharmaceutical drug sample. 
For the validation of the quantification method, the process just described was performed 
9 times for the sample pharmaceutical drugs and then, in one of the 9 samples, 1.0 mL of an 
auxiliary standard added to the matrix. In an empty Teflon vessel, a blank solution was also 
prepared, adding just the (1.5 mL of nitric acid, 0.5 mL of hydrochloric acid and 0.1 mL of 
hydrogen peroxide). 
Subsequently, all the vessels were properly closed, accommodated in a carousel, placed 
in the CEM - MDS-81D microwave oven equipped with 10 Teflon vessels and undergone a 
microwave program with a ramp of 10 minutes to 170 ºC and holding 10 minutes at 170 ºC.   
Ended the program, the vessels were let to cold, reach the room temperature and then opened. 
The samples were transferred to a properly identified plastic test tube, diluted to the mark 
(25 mL) with ultrapure water and weighed. 
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It were prepared seven standard solutions to perform the calibration curves with 
concentrations of 0; 0,1; 0,5; 2,0; 10; 50; 100 µg/L. In order to prepare these standard 
solutions, it was prepared a mother solution with elements concentration of 10 mg/L. 
Aliquots of 0; 0,5; 2,5; 10; 50; 250 and 500 µL were pipetted form the mother solution to 
plastic volumetric flasks of 50 mL. The volumetric flasks were properly identified, and the 
volumes diluted to the mark with a solution of 1% of HNO3. 
 
4. TECHNIQUES FOR THE DETERMINATION OF ELEMENTAL 
IMPURITIES IN PHARMACEUTICAL DRUGS  
In literature, several analytical methods are reported for the determination of trace and 
ultra-trace elements in pharmaceutical drugs. Typically, these methods require sample 
preparation, which are normally wet-acid digestion of samples or introduced in the form of 
a slurry in the equipment although there are several others sample preparation techniques 
(Zachariadis and Sahanidou, 2011) as mentioned before.  
The chapters of the European Pharmacopoeia (2.4.8), for the determination of trace and 
ultra-trace elements, describes as limit tests, the precipitation of the element of interest as 
sulphide, followed by visual examination comparing with lead standard solutions. Never-
the-less, this practice seems no longer be adequate to the actual demanding requirements of 
the pharmaceutical regulation (da Silva et al., 2017). In addition, the main disadvantages of 
these techniques are the non-specific and non-sensitive determination of the analytes and 
also the time-consuming digestion or ignition procedures and therefore there is a rising 
tendency to replace the simple trace elements test for modern instrumental techniques (Wang 
et al., 2003; Zachariadis and Kapsimali, 2006). 
Atomic absorption spectrometry is typically applied for single element analysis (Kelkó-
Lévai et al., 1999; Van Staden and Hattingh, 2000; Wang et al., 2003; Zachariadis and 
Kapsimali, 2006), as well as atomic emission spectrometry (Wang et al., 2003, 1999) 
although the last one requires digestion of the pharmaceutical drug (Zachariadis and Michos, 
2007). There are also different spectrometric and spectroscopic techniques like graphite 
furnace atomic absorption spectrometry (GF-AAS) or flame atomic absorption spectroscopy 
(F-AAS). Nonetheless, all of these techniques have a major disadvantage as they only 
analyze one element at the time. 
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In other hand, inductively coupled plasma atomic emission spectrometry (ICP-AES) 
(Nölte, 2003a; Thomas, 2004), and mass spectrometry (ICP-MS) (Amaral et al., 2015; 
Lewen, n.d.; Volker Thomsen, Debbie Schatzlein, 2003) have also been reported for the 
analysis of  pharmaceutical drugs having the advantage of presenting multielement analysis 
and allowing the quantification of much lower concentration values even for ultra-trace 
elemental impurities. This fact is of major importance since the pharmaceutical regulatory 
framework forces to quantify impurities present in bulk preparations and in finished drug 
products and, ensure that the concentration of the analysed elements are below the permitted 
daily exposure. However, most of the times these elements are in trace or ultra-trace amounts 
(da Silva et al., 2017). 
Apart from the inductively coupled plasma with mass spectrometry technique that is 
explored in more detail in the topic 6.1.1 below, all the other techniques (inductively coupled 
plasma atomic emission spectrometry, flame atomic absorption spectroscopy and graphite 
furnace atomic absorption spectrometry) are approach in more detail in ANNEX I. 
 
4.1. INDUCTIVELY COUPLED PLASMA 
About the same time that flame-based instruments like flame atomic emission or 
absorption spectroscopy became outstanding, S.Greenfield and associates developed, in the 
mid-1960s, the first plasma-based instruments using direct current or microwave-induced 
systems. Non the less, due to the interference effects and plasma instability problems 
associated with the plasma-based instruments, flame-based spectrometry instruments 
dominated the analytical market for metals analysis (Greenfield et al., 1964). 
Years later, the problems associated with plasma-based spectrometry were overcome by 
using instead, an inductively coupled plasma (ICP) system. The possibility of sequential 
multielement analysis coupled with high sensitivity and shorter analysis time made this 
technique quite popular in the 1980s (Greenfield et al., 1964).  
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In an ICP system, there are three gases flowing into a torch (Figure 3) that is comprised 
of three concentric tubes typically made of quartz. An ICP gas flows in the outer tube, this 
gas is also known as cool gas, it flows in the range of 13–17 L/min and his primary role is 
to shape the plasma and ensure that the high temperature of the plasma does not melt the 
torch. The second gas flows into the central tube and is usually named as plasma gas, it flows 
in the range of 1 L/min and is the one that in fact is ionised and form the plasma. The last 
one is called carrier gas, it flows in the innermost ring and is responsible for carrying the 
sample into the plasma. 
 
Figure 3: Scheme of an ICP torch and respective components. 
 
The end of the torch is placed inside an induction coil (as seen in Figure 3) and supplied 
with a radio-frequency electric current that flows through the coil to create an 
electromagnetic field in which the plasma gas (usually argon) flows through. A high voltage 
discharge (electric spark) is applied to introduce free electrons into the gas stream. When 
these electrons pass through the electromagnetic field applied, they gain energy and they are 
accelerated. When they collide with the plasma gas, they transfer their energy and ionise the 
gas. This creates a set of ion-electron pairs that are, in turn, energized in the presence of the 
electromagnetic field creating a cascading effect as schematized in Figure 4 that outcomes 
in the formation of a plasma that is maintained as long as the radio-frequency current is at a 
sufficient intensity and the gas flow are preserved (Abou-Shakra, 2003). 
34 
 
 
Figure 4: Schematic representation of the cascading effect that originates and sustains 
the plasma. 
Argon plasma is characterized by a bluish-white emission colour due to the combination 
of the argon atomic spectrum and the continuous spectrum of ion-electron recombination’s 
that are taking place in the plasma. As the plasma also produces ultraviolet light, it is not 
suitable to look at it directly. 
The combined cooling systems and the central tube for the carrier gas provide plasma 
with a shape that allows the sample to be introduced without disturbing considerably the 
plasma or changing its composition (Abou-Shakra, 2003). It also affords a maximum 
temperature of approximately 10 000 K in the hottest region and an analytical zone around 
6 000 to 7 000 K in the cone-shaped region outside the quartz torch as seen in Figure 5 
(Thomas, 2001). 
 
Figure 5: ICP plasma representation and respective temperatures zones. 
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Nowadays, the ICP is commonly coupled with an atomic emission spectrometer (OES) 
or a mass spectrometer (MS). Given the nature of the analysed samples and the concentration 
of the elements present in them, throughout this work, it is only going to be used an ICP 
coupled with a mass spectrometer. 
ICP offers the advantages of a low sample size requirement, screening capability, 
element-specific information, quantitation and rapid sample throughput (Lewen et al., 2004). 
Both ICP-OES and ICP-MS also present a multielement capability which is a major feature 
regarding elemental impurities in pharmaceutical products. The low detection limits are 
typically in μg/L range for ICP-OES and up to ng/L range for ICP-MS (Nölte, 2003a; The 
United States Pharmacopeial Convention, 2013; Thomas, 2004). 
Although ICP is a really useful technique in the multielement analysis, the use of organic 
solvents (Montaser, 1998) or high amount of total dissolved solids (TDS) can put in jeopardy 
the ICP analysis and therefore, compromises have to be made so that a suitable analytical 
technique could be chosen (Niemelä et al., 2004). 
 
4.1.1. INDUCTIVELY COUPLED PLASMA – MASS SPECTROMETRY 
If ICP-OES has become one of the election techniques, ICP-MS is not far behind. In the 
past three decades, since the first unit sale back in 1983, it has become the most accurate 
choice in the detection and quantification of many trace and ultra-trace elements. 
This system, as shown in Figure 6, consists of an ion source coupled with a plasma 
sampling interface and a mass spectrometer. The ions produced by the plasma torch are 
extracted from the atmospheric pressure through an often-made Ni or Cu water-cooled 
sampling cone with a 0.5 - 1.0 mm orifice that is placed in the plasma, to a second more 
sharply angled cone. This second cone is called skimmer and in there, the pressure is lowered 
to 1 Torr through a rotary pump. 
Then, the ions pass to the ion lenses that are usually cylinders held at appropriate 
voltages that has the mission of focus ions into the mass spectrometer, which is usually a 
quadrupole system operating at 10−5 to 10−6 Torr. There, the ions are separated based on their 
mass-to-charge ratio and then, a detector receives the ion signal that are proportional to their 
concentration (Olesik, 1991). 
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Figure 6: Typical quadrupole ICP-MS system with various sample introduction options: 
electrothermal vaporization (ETV), laser probe or ablation (LA), and flow injection 
analysis-hydride generation (FIA-HG). 
 
Then, the sample concentration is determined through calibration with reference 
material that is certified. This certified material can be single or multi-element reference 
standards depending on what is analysed.  
There are other types of mass spectrometers like high-resolution ICP-MS nonetheless 
when speaking of trace elements analysis, quadrupole ICP-MS is preferred as it is very 
reliable and present the possibility of an unattended and overnight operation (Sneddon and 
Vincent, 2008).  
As reported, this technique has been increasingly used as a substitute for the out-dated 
limit test of trace and ultra-trace elements prescribed by the United States, European and 
British Pharmacopoeia for pharmaceutical drug substances, intermediates, and raw 
materials. An example is an article where is reported a multi-element inductively coupled 
plasma-mass spectrometry survey method as an alternative for the old test where the 
technique allows the results to be presented until the lows µg/g (Wang et al., 2000). 
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4.1.1.1. ADVANTAGES OF ICP-MS 
ICP-MS offers analysis speed as it can scan a mass spectrum in just a few seconds, 
depending on exact instrument settings. This technique is also able to move from mass to 
mass with high precision degree allowing the peak hopping analysis technique. Peak 
hopping consists in obtaining only one single point of data at the top of the peak of each 
element during the analysis. 
Additionally, ICP-MS has high sensibility archiving to detect trace quantity levels, well 
below a part per billion (ppb) or ng/g. These detection limits are up to 3 orders of magnitude 
superior to those archived with an ICP-OES device, much due to the fact that there is no 
fundamental source of continuum background in ICP-MS.  
ICP-MS quadrupole systems may present a high background noise caused by the ion 
optics of the quadrupole mass analyser, making it susceptible to background noise on the 
detector. Nevertheless, high-resolution ICP-MS possess a design that prevents any stray 
photon from reach the detector and has extremely high ion transport efficiency resulting in 
extremely low backgrounds (less than 0.2 counts per second). It also has the potential to 
minimize or even eliminate the molecular argon inconvenient using variable resolution.  
 In the case of metals detection, their characteristics provide a very low detection limit 
of <1ppq or less than 1 𝑓g/g and by variating the resolution of the system it is even possible 
to analyse each metal in such a resolution that eliminates any interferences without over 
solving it. For instance, the element 56Fe has it most common interference 40Ar16O due to 
the fact that this molecule has a very big peak that tails into the Fe peak, but with a 2500 
resolution this interference is reduced or eliminated.  
 
4.1.1.2. DISADVANTAGES OF ICP-MS 
If ICP-MS has great advantages, it also presents a couple of not so good qualities. 
Concerning the analysis of elements with ICP-MS quadrupole systems, it has the inability 
of resolving some target isotopes from molecular interferences as the instruments are only 
able to resolve a mass spectrum in one-unit resolution. Taking the last example, an ICP-MS 
quadrupole although it can differentiate 56Fe and 57Fe, it would not be able to differentiate 
56Fe (mass 55.9349) from the 40Ar 16O molecular species (mass 55.9573), which is very 
easily formed in an argon plasma.  
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This disadvantage can be solved using the technique called “cold plasma” but it would 
compromise the sensitivity. “Cold plasma” consists in lowering the radiofrequency power 
to low the plasma temperature. This way, the number of ionized argon particles is 
diminished, and the interference reduced (Sneddon and Vincent, 2008).  
The background noise is also an issue as it can be produced by ions that pass around the 
quadrupole but still reach the detector (stray ions) or ions that are precisely on axis in the 
quadrupole and therefore not mass selected. Photons can also reach the detector and produce 
a signal. Elements with ionization potentials lower than 9 eV exist mainly as singly charged 
ions in the plasma, yet as there is a poor transmission of ions from the atmospheric pressure 
plasma to the low-pressure spectrometer, the number of ions reaching the detector is limited. 
For instance, a solution of Mn with 10 ppm concentration, in plasma produces around 1.8 X 
1013 Mn+, but only 1 in 6 X 107 ions or less are detected, leading to a count rate of about 3 
Χ 105 Hz (Golightly and Montaser, 1992). This background noise results in degraded or 
reduces detection limits as it is directly proportional to variations in the background noise. 
Regarding the high-resolution ICP-MS analysers, as it uses an electromagnet to separate 
the masses, it has to change the magnetic field strength for each mass which takes 
significantly more time than changing the electrical field as it’s the case of quadrupole ICP-
MS, resulting in a relatively slow analysis speed (Olesik, 1991). 
Another disadvantage of the high resolution ICP-MS analysers is the mass drift. Due to 
the fact that at high resolutions the peaks are narrow and it turns much more difficult for the 
magnet to move exactly to the same mass every time a metal is determined, it is necessary 
to scanning across the entire peak which is more time-consuming than the “peak hopping” 
use in the quadrupole system (Sneddon and Vincent, 2008). 
 
4.1.2. ICP-OES VERSUS ICP-MS 
Comparing the two inductively coupled plasma techniques, it can be said that both 
techniques are used for similar goals, i.e., for the determination and quantification of trace 
and ultra-trace elements in several solutions including pharmaceutical drugs. The choice 
between this two is based on a commitment between the one that best fits the needs of the 
analysts and the costs that the technique involves. In Table 5 is shown a comparison of the 
main aspects of each technique (Georgiou and Danezis, 2015). 
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Table 5: Comparison between the analytical techniques ICP-MS and ICP-OES. 
ICP-OES ICP-MS 
ICP is used as the excitation source ICP is used as an ionization source 
Detection limits of sub-µg/mL (µg/g) Detection limits of sub-µg/L (ng/g) 
Uses peak intensity at a wavelength for 
quantitative determination 
Uses m/z values at wavelengths for 
quantitative determination 
Initial cost moderate, $75 + K for basic 
system 
Initial cost expensive, $150 + K for basic 
system 
Relatively straightforward to operate and 
moderate routine maintenance 
More complex to operate and a high 
degree of maintenance required 
Sequential and simultaneous capability Sequential and simultaneous capability 
Capable of direct solid sampling Capable of direct solid sampling 
Spectral interferences well documented 
and often avoidable 
Isobaric interferences well documented 
and often avoidable 
Chemical interferences well understood Chemical interferences well understood 
 
4.2. ICP VERSUS OTHER TECHNIQUES 
To facilitate the comparison between the several techniques described above on topic 
6.1.1 and in the ANNEX I, a summary table of the main characteristics of the techniques is 
presented next (Table 6). 
Table 6: Comparison of the four more used analytical techniques in pharmaceutical 
drugs impurities quantifications. 
Technique 
Characteristic 
F-AAS GF-AAS ICP-OES ICP-MS 
Detection Limits 
Very good for 
some elements 
Excellent for 
some elements 
Very good for 
most elements 
Excellent for 
most elements 
Sample 
throughput 
10 to 15 s per 
element 
3 to 4 min per 
element 
<3 min per 60 
elements 
<3 min per 73 
elements 
Dynamic Range 103 102 106 108 
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Semiquantitative 
analysis 
No No Yes Yes 
Isotopic Analysis No No No Yes 
Ease of use Very Easy Moderate Easy Moderate 
Method 
Development 
Easy Moderate 
Moderately 
Easy 
Moderate 
Unattended 
Operation 
No Yes Yes Yes 
Sample Volumes 
Required 
Large Very small Medium 
Very small to 
medium 
Interferences 
Spectral Few Few Many Few 
Chemical Matrix Many Many Very Few Some 
Physical Matrix Some Very Few Very Few Some 
Dissolved solids 0.5-5% >20% 0-20% 0.1-0.4% 
Costs 
Capital Costs Low Medium High Very High 
Running Costs Low Medium High High 
Cost per Analysis 
Few 
elements/high 
throughput 
Low High Medium Medium 
Many 
elements/high 
throughput 
Medium High 
Low to 
Medium 
Low to 
Medium 
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Offering detection limits in the range of the subparts per trillion (108), ICP-MS presents 
the lowest detection limits of all the techniques, making it a very attractive system when 
compared to other systems like F-AAS, GF-AAS or even ICP-OES. 
ICP-MS also presents clear advantages concerning it analysis speed, isotopic capability, 
multielement analysis ability characteristic and high versatility as it can be used with several 
hybrid techniques or coupled with other techniques like liquid chromatography (LC-ICP-
MS) (Rao and M. V. N., 2007). 
Comparing now the general costs of the equipment’s it is here that it is found the great 
disadvantages of the ICP-mass spectrometry. Comparing to all the other technique presented 
in the table above, the costs for purchase and running the instrument at consumables level 
(argon, super pure acids…), ICP-MS is the less attractive one as presents the highest costs. 
In addition, it is necessary highly trained and formed employees to carry the analytical 
analysis.  
Finally, when analysing complex matrices or samples, ICP-MS can generate great 
amounts of data that is very time-consuming to analyse and process as, although there are 
several softwares written to serve the purpose, it is vital a visual inspection of the analytical 
results by an experienced specialist (Cubadda, 2007; Hou and Jones, 2000; Thomas, 2004).  
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5. ELEMENTAL IMPURITIES QUANTIFICATION 
Previous to any analysis on ICP-MS, it is always performed an optimization and 
verification of the proper functioning of the equipment. In the case of the inductively coupled 
plasma with mass spectrometry, the calibration is made daily before the analysis through 
auto-tune. The auto-tune choses the ideal conditions for the day, maximizing the internal 
standard signal (in this case the isotope 115In) and screening the reasons 140Ce16O/140Ce and 
69Ga/138Ba in order to minimize the formation of oxides and double charge species. Only 
then the isotopes of the to be analysed elements and the possible interferents are chosen and 
the analytical calibration initiated. The analytical calibration is performed through the 
analysis of the blanks and standard solutions referred on topic 3 of CHAPTER II and the 
calibration function defined with the blanks and standard solutions that presented less than 
10% of relative error. After the calibration, the analysis is carried on, interpolating the 
sample analysis the analysis of the washing solution (1% (v/v) of nitric acid) to ensure the 
validity of the results.  
 
6. EQUIPMENT USED 
For the determination of elemental impurities, it was used an inductively coupled plasma 
with a mass spectrometer Thermo X Series (Thermo Scientific) ICP-MS equipped with a        
3-channel peristaltic pump, a Burgener nebulizer and nickel cones. In the determination of 
each elemental impurity was used a different isotope with a specific atomic mass unit as 
described in Table 7. 
Table 7: Atomic mass units set for the determination of each element. 
Element Atomic mass units 
Cr 52 
Cu 65 
Mn 55 
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1. VALIDATION OF QUANTIFICATION METHODS FOR 
PHARMACEUTICAL DRUGS 
When dealing with quantification of compounds of interest through analytical methods, 
as it is the case of the quantification of trace and ultra-trace elements in pharmaceutical 
drugs, there is a need to evaluate both the quality of the instruments used and the quality of 
the results obtained. This evaluation is achieved by performing the validation of the testing 
method by running several tests of well establish parameters. The results obtained in this 
validation must correspond to the quality control established by the laboratory (RELACRE, 
2000). 
In order to produce valid results, there is a need to follow some rules as the use of 
methods and equipment which have been tested to ensure that they are suitable for the 
analytical measurements. These measurements should always be carried out by qualified and 
competent staff for the proper execution of the method and the quality control and quality 
assurance of the procedures must be always well-defined. An independent evaluation of the 
laboratory performance should be periodically executed and the analytical measurements 
results carried out in the evaluated laboratory must be consistent with those carried out in 
other laboratories (eurachem, 2014). 
 
1.1.  METHOD PERFORMANCE PARAMETERS 
To ensure the laboratory quality, performance parameters to evaluate have to be defined 
in order to acquire an adequate level of confidence in the results. It is also important to 
highlight that there has to be a balance between technical possibilities, costs and risks, as 
declared for the NP ISO / IEC 17025 (IPQ, 2005). 
Therefore, the method performance parameters that were studied in LCA (Laboratório 
Central de Análises) are presented next. 
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1.1.1. SPECIFICITY AND SELECTIVITY 
The terms specificity and selectivity are often used misguidedly and therefore it is 
important to differentiate them. In one hand, specificity refers to a method that produces a 
single response to a single analyte. On the other hand, selectivity refers to a method that 
provides several responses to various analytes that can be differentiated from each other or 
not. In other words, a method can be considered selective if the response to the analyte can 
be distinguished from the responses of the other constituents of the sample.  
The specificity and selectivity of the method are evaluated through an interference study 
where the interferences can be either isobaric (additives) or matrix (multiplicative). Isobaric 
interferences are evaluated through possible elementary or molecular interferents study, 
while matrix interferences are evaluated through recovery tests (NATA, 2013). 
 
1.1.1.1. MATRIX INTERFERENCES 
Recovery tests were performed in order to determine this parameter. These tests 
consisted of the addition of analyte volumes with well-known concentrations to the samples 
that are going to be analysed by ICP-MS. The Equation 1 presented next is then applied to 
the results and the recovery % calculated: 
𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦 (%) =  
[(𝐶𝑓 × 𝑉𝑓) − (𝐶𝑎 × 𝑉𝑎)]
𝐶𝑎𝑑𝑖𝑐 × 𝑉𝑎𝑑𝑒𝑑
 ×   100 
Equation 1 
Where: 
𝐶𝑓 – Analyte concentration in the fortified sample; 
𝐶𝑎 – Analyte concentration in the sample; 
𝐶𝑎𝑑𝑖𝑐 – Analyte concentration in the fortification solution; 
𝑉𝑓 – Volume of the fortified sample; 
𝑉𝑎 – Sample volume; 
𝑉𝑎𝑑𝑒𝑑 - Volume added of fortification solution. 
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1.1.1.2. ISOBARIC INTERFERENCES 
When analysing samples by ICP-MS, this parameter is evaluated by considering the 
respective interferences of the isotopes that are going to be analysed as described in ISO 
17294. A mono-elementary standard solution containing the possible interferent is analysed 
and it is verified if the intensity of the interferent in the analyte signal is higher or lower than 
the detection limit. In other words, it is verified if the interference is significant, and if so, 
the interference factor (𝑓), a function that relates the analyte and interference signals is 
calculated and applied. It is considered to have been successfully applied when it is found 
that the analyte concentration in the mono-elementary standard solution containing the 
interferent is lower than the detection limit (ISO, 2004, 2003).  
 
1.1.2. LIMIT OF DETECTION AND QUANTIFICATION 
There are different forms to perform the calculation of the detection and quantification 
limits that are recommended by the International Union of Pure and Applied Chemistry. One 
is the experimental determination in which the mean and standard deviation of n test readings 
performed on the blank sample is calculated. In this case, the analysis shall be performed 
under intermediate precision conditions, which shall be independent, and the following 
Equation 2 and 3 should be applied for the calculation of the limits of detection (LOD) and 
quantification (LOQ) (respectively): 
𝐿𝑂𝐷 = 3𝑠0 
Equation 2 
𝐿𝑂𝑄 = 10𝑠0 
Equation 3 
Where, 
𝑠0- Standard deviation associated with the n blank solution readings values.  
 
Another way is to admit that the quantification limit value corresponds to the value 
of the lowest standard solution concentration of the calibration curve. In this case, the 
value of the detection limit should be one-third of the quantification limit value. 
When defining both the limit of quantification and the limit of detection, it should be 
paid attention to the type of sample and the equipment capacity as, although for most 
equipment’s the coefficient of variation and the average relative error associated with the 
limit of quantification are in the order of 10%, these values may vary and be higher. This 
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is so important because the uncertainties associated with the quantifications must be 
consistent with the coefficient of variation and relative error mean values (eurachem, 
2014). 
 
1.1.3. WORKING RANGE 
Working range is defined as the analyte concentrations range in which the analytical 
method can be applied for analysis. Within the working range, the method is able to return 
values with an uncertainty value in accordance with the quality criteria accepted and 
estimated by the laboratory responsible for carrying out the analyses. This range usually 
corresponds to the linear zone of the calibration function and the upper and lower limits 
are usually defined by the concentration at which the equipment ceases to give a linear 
response (saturation) and by the quantification limit, respectively (eurachem, 2014). 
 
1.1.3.1. CALIBRATION CURVE 
For the proper analyte quantification, it is imperative the construction of calibration 
curves. This calibration curves are composed by, at least, 5 standard solutions throughout 
the working range. It must be calculated, a total of 5 independent calibration curves in 3 
independent days. It is only considered for the construction of the calibration curve, the 
standard solutions that present a standard deviation below the maximum limit stablished 
by the laboratory quality control. 
 
1.1.3.2. SENSITIVITY 
Sensitivity is defined as the ability to generate variation in the value of the studied 
property by the analytical method used. This variation of the response signal in function 
of the analyte variation, in practice, translates into the slope of the calibration curve. If 
the calibration curve is linear, the sensitivity will be constant and independent of the 
concentration of the analyte, if the calibration curve is not linear, then the sensitivity will 
be dependent of the analyte concentration and therefore not constant. The method 
sensitivity is higher, the higher the slope of the calibration curve, which means that with 
the same variation of analyte concentration a bigger response (signal) variation is 
obtained (Skoog et al., 2014). 
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1.1.3.3. CORRELATION COEFFICIENT 
The correlation coefficient measures the correlation degree between two variables x 
and y. The correlation coefficient should present a value higher than 0.995 accordingly to 
the LCA (Laboratório Central de Análises) quality control parameters established.  
 
1.1.3.4. LINEARITY 
The ability of an analytical method to demonstrate that the results obtained are 
directly proportional to the analyte concentration is referred to as linearity. This criterion 
can be evaluated using the Mandel test, applying the Equation 4: 
𝐹𝑡𝑒𝑠𝑡 =
(𝑁 − 2) × 𝑠𝑒,2
2 − (𝑁 − 3) × 𝑠𝑒,3
2
𝑠𝑒,2
2  
Equation 4 
 
Where, 
N – Number of standards used in calibration; 
𝑠𝑒,𝑥 - Residual standard deviation associated with the linear calibration function and 
the quadratic calibration function. 
 
The value of the Ftest is compared with the value of the Fisher distribution (F) for a 
95% confidence level and if the value of Ftest is lower than F, then the best calibration 
function is the linear as the quadratic calibration function does not lead to a significantly 
better adjustment. 
This test evaluates whether the variances associated with a linear function and a linear 
quadratic function are significantly different or not. Linearity deviations may occur in 
specific cases such as the lack of linearity of the detector response by saturation or due to 
chemical effects derived from the sample matrix. To avoid affecting the quality of the 
results, the upper working range limit value is defined as the point from which the slope 
of the calibration function deviates from the linear behaviour, and therefore it is advisable 
not to work above it (Skoog et al., 2014). 
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1.1.4. TRUENESS, PRECISION AND UNCERTAINTY 
In quality control is important to ensure the agreement degree between the measured 
value and the true value of an analyte (IPQ, 2012). This parameter is evaluated by trueness 
and precision  which are by their turn, related to total error that are likely to occur during 
an analytical assessment, namely systematic and random errors, as best exemplified in 
Figure 7 (eurachem, 2014). 
 
Figure 7: Relationship between types of errors, performance characteristics and 
their quantitative expression. 
 
1.1.4.1. TRUENESS 
The approximation between the mean of a number of values repeatedly measured and 
the reference value is defined as trueness. This parameter is usually evaluated by 
calculating the relative error or in terms of bias. However, given the nature of the analyte 
to be analysed in this work and has said before, there is no certified reference material to 
use in this parameter’s calculation, and therefore, it is only possible to apply the process 
of standard addition (recovery tests). For the standard addition method, it is necessary to 
add an aliquot of a multielement solution to the samples. The multielement solution is of 
well know concentration and contains all the elements that we want to analyse. 
This parameter is estimated by calculating the standard uncertainty associated with 
the trueness using the values of the recovery tests performed and applying the Equations 
5 and 6 (RELACRE, 2018). 
 
?̅? =
𝐶𝑜𝑏𝑠̅̅ ̅̅ ̅̅
𝐶𝑓𝑜𝑟𝑡𝑖𝑓
 
Equation 5 
µ𝑣𝑒𝑟(?̅?) = ?̅?√(
𝑠𝑜𝑏𝑠
2
𝑛 × 𝑐𝑜𝑏𝑠̅̅ ̅̅ ̅
2) + (
µ(𝑐𝑓𝑜𝑟𝑡𝑖𝑓)
𝑐𝑓𝑜𝑟𝑡𝑖𝑓
)
2
 
Equation 6 
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Where, 
𝐶𝑜𝑏𝑠̅̅ ̅̅ ̅̅  - estimated mean of the concentration of n tests of fortified samples; 
𝐶𝑓𝑜𝑟𝑡𝑖𝑓 – Element concentration in the fortification sample added; 
𝑠𝑜𝑏𝑠- Standard deviation of the series of n test results of fortified samples; 
n - Number of fortified sample tests; 
µ(𝑐𝑓𝑜𝑟𝑡𝑖𝑓) - standard uncertainty associated with the element concentration in the 
fortification sample. 
 
1.1.4.2. PRECISION 
Precision is defined as the level of agreement, under specific conditions, between 
values obtained by repeating measurements between similar samples or the same sample. 
It is evaluated through studies that use several replicates of different samples or patterns 
that fit within the working range. These studies are usually measurement reproducibility, 
repeatability and intermediate precision (eurachem, 2014). 
 
1.1.4.2.1. REPLICATION 
This parameter is analysed using duplicate analysis. Control charts are also shown 
for the relative difference between duplicate readings whether they are from the same 
sample or not. The following expression (Equation 7) is used to calculate the relative 
difference between duplicate analyses: 
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 (%) =
𝐶2 − 𝐶1
𝐶̅
× 100 
Equation 7 
Where, 
𝐶2 𝑎𝑛𝑑 𝐶1- Concentrations obtained for the sample reading and the duplicate, 
respectively; 
𝐶̅- Mean of the duplicate readings concentration. 
 
This parameter allows evaluating drifts that may occur during the analyte 
quantification process as the sample is analysed at the beginning of the analysis and the 
duplicate at the end of the run. 
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1.1.4.2.2. RELATIVE STANDARD DEVIATION 
The sample variation coefficient is obtained by calculating the relative standard 
deviation of three reading for the same sample using Equation 8. This coefficient also 
permits the determination of the concentration from which the desired analyte can be 
quantified since it tends to increase as the analysed samples concentrations are closer to 
the quantification limit. 
𝑅𝑆𝐷 =
𝑠
?̅?
 
Equation 8 
Where, 
s - Standard deviation associated with the three reading for the same sample; 
?̅? – Mean of the three readings of the same sample. 
 
1.1.4.2.3. REPEATABILITY  
Repeatability corresponds to the dispersion of the results obtained for the same 
sample or standard, under the same conditions and expresses the lowest variation 
associated with the results. The repeatability limit allows us to know whether, under 
repeatability conditions, the difference between duplicates of a sample is significant or 
not. 
For the evaluation of this parameter, the sample are prepared and analysed in-between 
of other samples in order to evaluate the variability of the digestion and preparation of 
the samples and the variability associated with the quantification process. 
The estimated repeatability variation is determined using Equation 9: 
𝑠𝑟𝑖
2 = [
∑(𝑥𝑖 − ?̅?)
𝑛 − 1
]
2
 
Equation 9 
Where, 
𝑥𝑖 - Individual values considered; 
?̅? – Mean of the individual values considered; 
n - number of readings performed for each sample. 
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Then, for a 95% confidence level, the limit of repeatability (r) is calculated following 
the Equation 10 and the variation coefficient (VCr) determined, in percentage, for each 
sample or standard following the Equation 11: 
𝑟 = 2.8 × √𝑠𝑟𝑖
2  
Equation 10 
𝐶𝑉𝑟 =
𝑠𝑟𝑖
2
?̅?
× 100 
Equation 11 
 
1.1.4.2.4. INTERMEDIATE PRECISION 
Intermediate precision quantifies the variation associated with the results of the same 
sample or standard evaluated in the same laboratory by the same method and operator but 
on independent days. Intermediate precision (Si) can be determined by combining the 
within-group variance (associated with repeatability) and the variation between groups 
obtained using the Equation 12. Within-group variance can be obtained directly from an 
ANOVA table corresponding to the sum of the squares mean within the group (MSw) 
(eurachem, 2014) and the variation between groups with Equation 13. 
 
𝑆𝑖 = √𝑀𝑆𝑤 + 𝑆𝑏𝑒𝑡𝑤𝑒𝑒𝑛
2  
Equation 12 
𝑆𝑏𝑒𝑡𝑤𝑒𝑒𝑛 = √
𝑀𝑆𝑏 + 𝑀𝑆𝑤
𝑛
 
Equation 13 
Where, 
𝑆𝑏𝑒𝑡𝑤𝑒𝑒𝑛- Standard deviation associated with the between-group variation; 
𝑀𝑆𝑏- Sum of the between-groups squares mean; 
𝑀𝑆𝑤 - Sum of the within-group squares mean; 
𝑛 – Number of sample readings. 
 
1.1.4.3. UNCERTAINTY 
The uncertainty can be defined as a non-negative measure that characterizes the 
dispersion of the values obtained from the analyte analysis (IPQ, 2012). In order to calculate 
the estimated uncertainty, the data obtained in the validation process are used among the 
Equation 14. 
µ𝑅𝑤 = √µ𝑅𝑤,𝑠𝑡𝑎𝑛𝑑
2 + µ𝑟,𝑟𝑎𝑛𝑔𝑒2  
Equation 14 
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Where, 
µ𝑅𝑤,𝑠𝑡𝑎𝑛𝑑- Uncertainty component of the results from the standard solution; 
µ𝑟,𝑟𝑎𝑛𝑔𝑒- Uncertainty component from the range control chart. 
 
It is important to highlight that for the estimation of both uncertainty contributions it is 
needed a minimum of eight measurements. 
 
1.2. VALIDATION OF THE Mn QUANTIFICATION METHOD FOR 
PHARMACEUTICAL DRUGS 
For the validation of the quantification methods process, it was used two different 
samples. For Brufen sample, it was validated the quantification methods of Cr and Mn while 
for Maalox sample, it was validated the quantification methods of Cr, Mn and Cu. In all the 
cases the elements quantification was performed using an inductively coupled plasma - mass 
spectrometry. For that, it was followed the DQ.PSQ.019 lab internal methods validation 
procedure. 
Given that all the methods validated undergone an identical analysis and treatment 
process, it is only going to be shown the validation process of the Mn quantification for 
Brufen and Maalox as an example. All the others validation methods processes are shown in 
more detail in ANNEX II. 
 
1.2.1. SPECIFICITY AND SELECTIVITY 
Both specificity and selectivity were evaluated through interference studies. 
 
1.2.1.1. RECOVERY TESTS - MATRIX INTERFERENCES EVALUATION 
For each pharmaceutical drug there were performed on 3 independent days, 9 recovery 
tests each day. In each day, the same amount of analyte was added to the samples to ensure 
fortified one. The control charts of the Mn recovery test percentages in Brufen and Maalox 
matrices are shown in Figure 8 and Figure 9, respectively. Both charts presented several 
sample recovery % that can be from the same day of analysis or not. Thus, some tendencies 
may seem to occur, however, it does not mean that the process is out of control (RELACRE, 
1996). 
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Figure 8: Control chart of Mn recovery tests in Brufen samples. 
 
 
Figure 9: Control chart of Mn recovery tests in Maalox samples. 
 
Figure 8 and Figure 9 allow to verify that medium recovery percentage of Mn for 
Brufen samples is 100% while for Maalox is 103%. In both cases, there were made 24 
recovery tests and in all of the Brufen samples, the recovery percentages obtain were 
between 98% and 104% with the exception of the 6th recovery test that presents a recovery 
percentage of 90%. In Maalox samples, the recovery percentages verified were between 102 
and 104%. Since that the acceptance criteria range for recovery tests establishes by the 
laboratory (LCA) is between 80% and 120%, it can be said that all the recovery tests obtained 
for both pharmaceutical drugs are within the quality limits required.  
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The control charts referring to the validation process of all the other elements (Cr for 
Brufen and Cr and Cu for Maalox) are presented in ANNEX II. They present similar results 
to that obtained above for Mn, being that all the recovery percentages obtained are within 
the acceptance criteria range defined by the laboratory. The recovery percentages for Brufen 
samples are between 98% and 110% for Cr. For Maalox samples were obtained recovery 
percentages between 108 and 113% for Cr (with the exception of the 8th recovery test that 
presents a recovery percentage of 102%) and within 90% and 93% for Cu.  
As already said, the 6th test of Mn recovery tests in Brufen presents a recovery percentage 
of 90% and the 8th recovery test of Cr in Maalox presents a recovery percentage of 102%, 
which are, in both cases, within the quality standards defined by the laboratory. Nonetheless, 
by further analysis of the respective control charts, it can be notice that the recovery tests 
mentioned are out of control. Therefore, the 6th and 8th recovery test mentioned were 
considered outliers and excluded from the remain performance parameters calculations. 
With the exception of the cited recovery tests, all of the other recovery tests obtained for the 
analysed elements in both Brufen and Maalox are under control and within the quality 
control limits stablished by the laboratory. Thus, it may be concluded that, for the analysed 
elements, there weren’t registered significant matrix interferents.  
Regarding the isobaric interferences, all of the interferent concentrations detected were 
lower than the quantification limit and therefore no interference corrections were performed. 
Given that all of the recovery tests were within the quality control standard defined by LCA 
and there weren’t registered isobaric interferences, it can be said that the quantification 
methods tested are all selective and specific. 
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1.2.2. LIMIT OF DETECTION AND QUANTIFICATION 
Figure 10 and Figure 11 presented the charts for the obtained absolute values of the 
blanks concentrations regarding the quantification of Mn. It is represented as well, in each 
chart, the estimated limit of detection (yellow line) and limit of quantification (red line). 
 
Figure 10: Verification chart of the values obtained after digestion of blank solutions 
concerning the determination of Mn and respective limit of detection (LOD) and limit of 
quantification (LOQ). 
 
Figure 11: Verification chart of the blanks solution values concerning the 
determination of Mn and respective limit of detection (LOD) and limit of quantification 
(LOQ). 
 
The LOD and LOQ lines represented in both charts were calculated following the 
Equations 2 and 3 presented in topic 1.1.2 of CHAPTER III. Both equations used and the 
values obtained are presented in Table 8. 
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 Table 8: Equations and respective values of limit of detection (LOD) and limit of 
quantification (LOQ) for digestion blank and blank solutions regarding Mn quantification. 
Equation Digested blank Blank solutions  
𝑳𝑶𝑫 = 𝟑𝒔𝟎 2,97E-01µg/L 1,28E-01µg/L 
𝑳𝑶𝑸 = 𝟏𝟎𝒔𝟎 9,00E-01µg/L 3,87E-01 µg/L 
 
Table 8 shows that the values of LOD and LOQ are higher in the case of the digested 
blanks than in the blank solution. This registered difference could be due to a small portion 
of analyte that is being introduced inadvertently during the blanks preparation and digestion. 
In these cases, the limits that are established are always the highest values and therefore, the 
limit of detection is establish as 2,97E-01 µg/L and the limit of quantification establish as 
9,00E-01µg/L, for Mn quantification. 
The detection limit established for Cr is 1,22E+00 µg/L and 1,11E+00 µg/L for Cu. The 
quantification limits determined are 3,70E+00 µg/L for Cr and 3,37E+00 µg/L for Cu. All 
the calculation of the LOD and LOQ of the two elements just mentioned (Cr and Cu) are 
presented in more detail in ANNEX II. 
The LOQ value cannot be experimentally confirmed or either subjected to the trueness 
error evaluation as the PVLQ (quantification limit verification standards) cannot be prepared 
due to the lack of certified reference materials for pharmaceutical products.  
 
1.2.3. WORKING RANGE 
Previously to each analysis, a calibration curve is calculated and established by the 
equipment software. Nonetheless, for academical purposes, the calibration curves 
calculations were performed for Mn and are presented in Tables 9 to 11.  Figure 12 
represents the obtained function that validates the equipment software calculations. 
All of the calculations and verification of the calibration curves, as well as all the 
quantification parameters for Cr and Cu, are presented with more detail in ANNEX II. 
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Table 9:  Parameters and respective values for the construction of the linear 
calibration function for Mn. 
Standard Conc. (µg/L) Signal (cps) si si2 si-2 
P 0,0 0,000 7,17E+02 0,00 2,00E-06 5,00E+05 
P 0,1 0,100 8,99E+02 0,00 2,00E-06 5,00E+05 
P 0,5 0,500 1,59E+03 0,01 1,62E-04 6,17E+03 
P 2,0 2,00 4,22E+03 0,05 2,05E-03 4,88E+02 
P 10 10,0 1,86E+04 0,09 8,45E-03 1,18E+02 
P 50 50,0 9,29E+04 0,61 3,72E-01 2,69E+00 
P 100 100 1,83E+05 0,37 1,39E-01 7,17E+00 
Sum 1,63E+02 3,02E+05 1,14E+00 5,22E-01 0,00E+00 
Mean 2,32E+01 4,31E+04 1,62E-01 7,46E-02 0,00E+00 
 
Table 10: Parameters and respective values for the construction of the linear 
calibration function for Mn - Continuation. 
Standard 
Conc. 
(µg/L) 
wi wi*xi wi*yi wi*xi*yi wi*xi2 
P 0,0 0,000 3,48E+00 0,00E+00 0,00E+00 2,49E+03 6,21E+06 
P 0,1 0,100 3,48E+00 3,48E-01 1,21E-01 3,13E+03 9,77E+06 
P 0,5 0,500 4,29E-02 2,15E-02 4,60E-04 6,82E+01 4,65E+03 
P 2,0 2,00 3,39E-03 6,79E-03 4,61E-05 1,43E+01 2,05E+02 
P 10 10,0 8,23E-04 8,23E-03 6,77E-05 1,53E+01 2,34E+02 
P 50 50,0 1,87E-05 9,34E-04 8,72E-07 1,73E+00 3,01E+00 
P 100 100 4,99E-05 4,99E-03 2,49E-05 9,12E+00 8,32E+01 
Sum 1,63E+02 7,00E+00 3,90E-01 1,21E-01 5,73E+03 1,60E+07 
Mean 2,32E+01 1,00E+00 5,57E-02 1,74E-02 8,18E+02 2,28E+06 
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Table 11: Calibration standards residual error value (%) for Mn. 
Standard 
Conc. 
(µg/L) 
Calculated 
Signal 
(cps) 
Residual 
Residual 
Error 
(%) 
Calculated 
[Mn] 
(µg/L) 
|Relative 
Error| 
(%) 
P 0,0 0,000 7,17E+02 1,24E-01 0,020 6,80E-05 - 
P 0,1 0,100 8,98E+02 5,09E-01 0,060 1,00E-01 0,280 
P 0,5 0,500 1,62E+03 -3,69E+01 -2,33 4,80E-01 4,07 
P 2,0 2,00 4,35E+03 -1,27E+02 -3,01 1,93E+00 3,50 
P 10 10,0 1,89E+04 -2,82E+02 -1,52 9,84E+00 1,55 
P 50 50,0 9,15E+04 1,34E+03 1,44 5,07E+01 1,47 
P 100 100 1,82E+05 5,12E+02 0,280 1,00E+02 0,280 
 
 
Figure 12: Experimental data collected and respective linear calibration function for 
Mn. 
 
Table 12 shows the weighted calibration function parameter, namely the slope, y-
intercept and correlation coefficient. For all of the elements validated in this work, the 
calibration function was calculated with, at least, 5 standard solutions distributed through 
the working range. For all of the weighed calibration functions obtained were verified a 
correlation coefficient not less than 0,999985. 
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Table 12: Weighted calibration function parameters for Mn. 
bw aw  r 
7,17E+02 1,82E+03 0,999948 
 
Based on the results obtained, it can be settled that the instrumental working range for 
the Mn quantification is defined by the limit of quantification and the value of the higher 
standard solution concentration, in other words, the working range is 0,9 to 100 µg/L. Figure 
13 shows the residual error, in percentage, for the Mn calibration function. 
 
Figure 13: Residual error (%) for Mn quantification. 
 
LCA quality standards consider that the maximum acceptable percentage for residual 
error is 10%. Analysing Figure 13 it can be concluded that all of the calibration standard 
solutions analysed have less than 3% of residual error. The high correlation coefficient and 
the acceptable residual errors confirm that the weighted calibration linear function calculated 
for Mn is suitable for the obtained results. By further analysis of the figure, it can also be 
noticed that there aren’t more than 3 positive or negative consecutive residual error 
percentages. This means that the residual error does not present tendencies corroborating, 
even more, the suitability of the weighed linear function. 
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As described in ANNEX II, it was obtained a working range from 3,7 and 100 µg/L for 
Cr and for Cu from 3,4 to 100 µg/L. In all the cases the residual error (%) calculated was 
always below 10% and it was not verified more than 3 positive or negative consecutive 
residual error percentages. Therefore, it can be concluded that the residual error does not 
present tendencies in any of the cases and all of the weighted linear function obtained are 
suitable for the results obtained. 
 
1.2.4. TRUENESS, PRECISION AND UNCERTAINTY 
 
1.2.4.1. TRUENESS 
Trueness was evaluated through the control chart of the bias associated with the 
calibration curves verification standards (PVRCs). It was only calculated the bias associated 
with the element quantification using PVRCs as it is not possible to estimate trueness due to 
the lack of certified reference material. Figure 14 shows control chart of the bias associated 
with the quantification of Mn. The bias control charts referring Cr and Cu are presented in 
ANNEX II. 
 
Figure 14: Control chart of bias (%) for Mn quantification. 
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Figure 14 shows that in all cases the bias is lower than 8%. Given that the maximum 
value accepted for trueness by the laboratory is 10%, it is possible to conclude that the quality 
requirements stipulated are fulfilled and therefore, the LCA quality standards are suitable 
for the quantification of Mn in pharmaceutical drugs. It can also be concluded that the 
method is under control and there isn’t any significant error in the digestion process that 
affects significantly the trueness of the method. 
The control charts of the trueness associated with the element quantification for Cr and 
Cu are presented in detail in ANNEX II. The maximum value of bias estimated for Cr is 
8%, while for Cu is 9%. In sum, the quality standards of LCA are suitable for the 
quantification of all the elements mentioned and the quantification stage for all of the 
elements is under control, since the trueness were within the quality requirements established 
by the laboratory (10%). 
 
1.2.4.2. PRECISION 
 
1.1.4.2.5. RELATIVE STANDARD DEVIATION 
Each sample used in the validation process was analysed in 3 independent days and the 
relative standard deviation (RSD) was calculated. Figure 15 and Figure 16 presented the 
control chart of the relative standard deviation (%) for the Mn quantification in Brufen and 
in Maalox, respectively. The RSD control chart for Cu quantification in Brufen and Cu and 
Cr in Maalox are presented in ANNEX II. 
 
Figure 15: Control chart of the relative standard deviation (RSD, %) for Mn 
quantification in Brufen. 
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Figure 16: Control chart of the relative standard deviation (RSD, %) for Mn 
quantification in Maalox. 
 
The relative standard deviation maximum value, in percentage, for the quantification of 
Mn in Brufen was 43% and for the quantification of Mn in Maalox was 6%. In general, the 
RSD values are high, meaning that the values obtain have high dispersion in the sample 
quantification process. For the quantification of Cr was obtained a relative standard deviation 
maximum value of 43% for Brufen and 8% for Maalox. In the case of Cu quantification, the 
RSD maximum value obtained for the quantification of Cu in Maalox was 24 %. Based on 
the high values obtained for RSD, it can be concluded that there are drifts in the 
quantification process. 
The quality standards for methods validation suggests that RSD should be around 10 %, 
but this value might be superior depending on the analytical methodologies and the 
quantified parameters. Thus, the maximum quality criteria value for the RSD (%) should be 
altered for the maximum value mentioned in each case. 
  
1.1.4.2.6. REPEATABILITY  
Table 13 and 14 presented the repeatability variation coefficient of all the samples 
analysed in each day. It also shows calculated HORRATr values for Mn quantification in 
Brufen and Maalox, respectively.  
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Table 13: Estimated CVr (%) and HORRATr values for Mn quantification in Brufen. 
 Nº of 
readings 
CVr (%) HORRATr 
Day 1 7 78,9 36,6 
Day 2 8 20,4 8,94 
Day 3 8 34,7 14,8 
 
Table 14: Estimated CVr (%) and HORRATr values for Mn quantification in Maalox. 
 Nº of 
readings 
CVr (%) HORRATr 
Day 1 8 2,9 1,6 
Day 2 8 2,1 1,1 
Day 3 8 1,7 0,9 
 
As it can be seen in Table 13 the HORRATr values are all higher than 2, which means 
that the method repeatability is not satisfactory. This may be due to the fact that Mn 
concentrations obtained were close to the LOQ which difficult repeatability evaluation as it 
leads to a higher result dispersion than expected. In the case of Mn quantification in Maalox 
(Table 14), the HORRATr are in all the cases lower than two meaning that in this case the 
repeatability was satisfactory. 
Tables showing the values of CVr(%) and HORRATr for the quantification of Cr for 
Brufen and Maalox and Cu for Maalox are presented in ANNEX II. In all cases the method 
repeatability was not satisfactory. 
 
1.1.4.2.7. INTERMEDIATE PRECISION 
Table 15 presents the several CVSI (%) obtained for Mn quantification in Brufen and 
Maalox and also the number of groups evaluated (p), the number of readings executed and 
the calculated HORRATSI values. 
Table 15: Estimated values of CVSI (%) and HORRATSI for Mn quantification in 
Brufen and Maalox. 
Pharmaceutical 
Drug 
CVSI (%) p n HORRATSI 
Brufen 66,3 3 23 29,5 
Maalox 3,8 3 23 2,09 
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HORRATSI values are in both cases superior to 2, although in the case of Maalox the 
value is very close to 2. This occurrence shows the precision between days is not satisfactory. 
This is probably manly due to the low concentration of analyte as it difficult the element 
quantification and leads to higher variation coefficients. It can also be due to the high 
complexity of the matrices. 
For other elements, results were similar, being in all the cases the value of HORRATSI 
higher than 2. The estimated values of CVSI (%) and HORRATSI for Cr in Maalox and Brufen 
and Cu in Maalox are presented in ANNEX II. In sum, in all cases the precision between 
days was not satisfactory and it should be performed more tests to estimate the intermediate 
precision. 
 
1.3. SUMMARY OF METHODS VALIDATION FOR PHARMACEUTICAL 
DRUGS  
It was possible to validate the quantification method of the elemental impurities Mn and 
Cr in the pharmaceutical drugs Brufen and Maalox and Cu in Maalox. The performance 
parameters evaluated, and respective results are summarized in Tables 16 to 18. 
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Table 16: Performance parameters summary for Mn quantification in pharmaceutical 
drugs. 
Validation Parameters Required 
Mn in 
Brufen 
Mn in 
Maalox Observations 
Obtained 
Value 
Obtained 
Value 
S
p
e
c
if
ic
it
y
 
S
e
le
c
ti
v
it
y
 
Matrix 
Interferences 
80-120% 98-104 % 102-104 % 
Minimum and maximum 
value obtained 
L
O
D
 
L
O
Q
 
Limit of 
Detection 
n.a. 
9,27E-01 µg/L 
1,28E-01 µg/L 
Obtained with digestion 
and blank solutions, 
respectively 
Limit of 
Quantification 
n.a. 
9,00E-01µg/L 
3,87E-01 µg/L 
Obtained with digestion 
and blank solutions, 
respectively 
W
o
r
k
in
g
 R
a
n
g
e
 
Correlation 
Coefficient 
≥ 0,995 0,999948 n.a. 
Sensitivity/Slope n.a. 1,71E+03 n.a. 
Working Range n.a. 9,00E-01 to 100 µg/L n.a. 
P
r
e
ci
si
o
n
 
Trueness (bias) ≤ 10 % 3,7 % Maximum value obtained 
Sample 
Variation 
Coefficient 
≤ 10 % ≤ 43% ≤ 6% Maximum value obtained 
Repeatability 
Variation 
Coefficient 
≤ 10 % 34,7% 2,9% 
Maximum value obtained 
in digested sample replicas 
reading 
HORRATr < 2 14,8 1,6 Maximum value obtained 
Intermediate 
Precision 
≤ 10 % 26,5% 3,8% Maximum value obtained 
HORRATSI < 2 11,5 2,1 Maximum value obtained 
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Table 17: Performance parameters summary for Cr quantification in pharmaceutical 
drugs. 
Validation Parameters Required 
Cr in 
Brufen 
Cr in 
Maalox Observations 
Obtained 
Value 
Obtained 
Value 
S
p
e
c
if
ic
it
y
 
S
e
le
c
ti
v
it
y
 
Matrix 
Interferences 
80-120% 
98-110 % 108-113 % 
Minimum and maximum 
value obtained 
L
O
D
  
L
O
Q
 
Limit of 
Detection 
n.a. 
2,53E-01 µg/L 
1,22E+00 µg/L 
Obtained with digestion and 
blank solutions, respectively 
Limit of 
Quantification 
n.a. 
7,68E-01µg/L 
3,70E+00 µg/L 
Obtained with digestion and 
blank solutions, respectively 
W
o
r
k
in
g
 R
a
n
g
e
 
Correlation 
Coefficient 
≥ 0,995 0,999997 n.a. 
Sensitivity / 
Slope 
n.a. 1,75E+02 n.a. 
Working 
Range 
n.a. 3,70 to 100 µg/L n.a. 
P
r
e
ci
si
o
n
 
Trueness (bias) ≤ 10 % 7,87 % Maximum value obtained 
Sample 
Variation 
Coefficient 
≤ 10 % ≤ 43 % ≤ 8 % Maximum value obtained 
Repeatability 
Variation 
Coefficient 
≤ 10 % 19,6 % 5,1 % 
Maximum value obtained in 
digested sample replicas 
reading 
HORRATr < 2 10,4 2,8 Maximum value obtained 
Intermediate 
Precision 
≤ 10 % 28,6 % 5,9 % Maximum value obtained 
HORRATSI < 2 14,8 3,2 Maximum value obtained 
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Table 18: Performance parameters summary for Cu quantification in pharmaceutical 
drugs. 
Validation Parameters Required 
Cu in Maalox 
Observations 
Obtained Value 
S
p
e
c
if
ic
it
y
 
S
e
le
c
ti
v
it
y
 
Matrix 
Interferences 
80-120 % 90-93 % 
Minimum and maximum value 
obtained 
L
O
D
 
L
O
Q
 
Limit of 
Detection 
n.a. 
9,22E-01 µg/L 
1,1E+00 µg/L 
Obtained with digestion and 
blank solutions, respectively 
Limit of 
Quantification 
n.a. 
2,79E+00 µg/L 
3,37E+00 µg/L 
Obtained with digestion and 
blank solutions, respectively 
W
o
r
k
in
g
 R
a
n
g
e
 Correlation 
Coefficient 
≥ 0,995 0,999985 n.a. 
Sensitivity/Slope n.a. 1,71E+03 n.a. 
Working Range n.a. 
3,37E+00 to 100 
µg/L 
n.a. 
P
r
e
ci
si
o
n
 
Trueness (bias) ≤ 10 % 9,4 % Maximum value obtained 
Sample 
Variation 
Coefficient 
≤ 10 % ≤ 24 % Maximum value obtained 
Repeatability 
Variation 
Coefficient 
≤ 10 % 15,7 % 
Maximum value obtained in 
digested sample replicas reading 
HORRATr < 2 6,8 Maximum value obtained 
Intermediate 
Precision 
≤ 10 % 18,1 % Maximum value obtained 
HORRATSI < 2 7,6 Maximum value obtained 
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2. GENERIC AND REFERENCE PHARMACEUTICAL DRUGS 
ELEMENTAL IMPURITIES COMPARISON 
Samples of several generic pharmaceutical drugs and respective reference drugs were 
analysed and the elemental impurities V, Cr, Mn, Cu, Zn and Pb determined (Table 19). 
Although the quantification methods were not validated for all of the elemental impurities 
shown in the table below, it was still considered pertinent to show these values. 
 
Table 19: Concentration in µg/g of V, Cr, Mn, Cu, Zn and Pb in generic and reference 
pharmaceutical drugs. 
Pharmaceutical drug 
Cr Mn Cu Zn Pb 
µg/g µg/g µg/g µg/g µg/g 
Proton pump inhibitors 
Proton 0,46 0,28 < LOQ 1,29 0,02 
Proton Capsule 0,81 0,37 0,80 1,06 0,09 
Proton (Total) 1,27 0,65 0,80 2,34 0,11 
Omeprazol Generis 0,34 0,28 < LOQ 0,87 0,10 
Omeprazol Generis Capsule 0,52 0,30 0,42 0,64 0,11 
Omeprazol Generis (Total) 0,85 0,58 0,42 1,50 0,21 
Omeprazol Ratiopharm 0,88 0,16 0,25 1,27 0,16 
Omeprazol Ratiopharm Capsule 1,90 0,24 0,99 1,07 0 
Omeprazol Ratiopharm (Total) 2,78 0,40 1,25 2,34 0,29 
Pantoprazol Teva 0,53 1,04 < LOQ 0,95 0,35 
Lansoprazol Teva 0,98 0,10 0,19 0,57 0,08 
Lansoprazol Teva Capsule 1,45 0,28 1,42 1,40 0,32 
Lansoprazol Teva (Total) 2,42 0,38 1,60 1,98 0,40 
Non-steroidal anti-inflammatory drugs 
Brufen 0,69 0,29 0,14 0,38 0,04 
Ibuprofeno Azevedos 0,80 0,65 < LOQ 1,47 0,14 
5-alpha reductase inhibitors 
Combodart 0,35 0,77 1,27 0,58 0,03 
Durasterida Teva 0,25 0,18 0,24 1,99 0,02 
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Table 19 allow to verify that elemental impurities concentrations varies from one 
pharmaceutical drug to another. This finding corroborates the fact that the generic 
pharmaceutical drugs do not contain the same excipient as explained in topic 2.3.2 of 
CHAPTER I. 
In the case of the inhibitor of the proton bomb, it can be observed that in all of the 
pharmaceutical drugs analysed, the greatest amount of Cr, Mn and Cu is introduced in the 
pharmaceutical drug by the capsules as the concentrations of these elemental impurities in 
the capsules are substantially higher than in the her contents. In the cases of the Lansoprazol 
and Proton, in addiction of the already said elemental impurities, the greatest amount of Pb 
is also introduce by their capsules. 
By looking at the non-steroidal anti-inflammatory pharmaceutical drugs, one can see 
that, regarding the analysed elemental impurities, the generic pharmaceutical drug contains 
high elemental impurities concentration that their respective reference pharmaceutical drug. 
Nonetheless, it cannot be concluded that generic non-steroidal anti-inflammatory 
pharmaceutical drugs contain always more impurities than their reference drugs as it were 
only compared one generic with one reference pharmaceutical drug.  
Regarding the 5-alpha reductase inhibitors, with the exception of V and Zn, it is observed 
that the reference drug, Combodart, presents higher elemental impurities concentrations than 
the generic pharmaceutical drug Durasterida Teva.  
In all cases, even with the maximum intake of the pharmaceutical drug daily dosage 
recommended by the laboratory, the amount of elemental impurities ingested is well below 
the maximum permitted daily exposure to the elemental impurity (Table 3). Summing up, 
although the elemental impurities in generic pharmaceutical drugs are not safeguarded by 
the law, in the cases of the analysed pharmaceutical drugs there is any concerning situation.  
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3. CONCLUSIONS 
This work had as fundamental goals, develop and validate ICP-MS methods for the 
determination of elemental impurities in generic pharmaceutical drugs and compare the 
results with their reference drugs.   
The work allowed to propose a methodology to successfully dissolve and microwave 
digest the pharmaceutical drug samples. It was also accomplished the validation of the 
quantification methods by ICP-MS of Cr and Mn in the pharmaceutical drug Brufen and Cr, 
Mn and Cu in the pharmaceutical drug Maalox. 
Also, it was compared the differences regarding elemental impurities both in generic 
and reference pharmaceutical drugs; 
For all that has been said above, it can be concluded that the overall aim of this 
investigation, as well as, all of the specific goals described in the beginning of this work 
were successfully archived.  
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ANNEX I: OTHER ELEMENTAL IMPURITIES 
DETERMINATION TECHNIQUES 
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1.  FLAME ATOMIC ABSORPTION SPECTROSCOPY 
Flame atomic absorption spectroscopy is a quantitative analytical technique that 
measures the light absorption of free, ground state atoms. 
In F-AAS, the sample is aspirated through a capillary tube into the nebulizer where the 
sample solution is converted into an aerosol (similarly to ICP) and then, drops with diameter 
< 20 µm are carried to the burner head as schematized in Figure 17.  
 
Figure 17: Injection system and burner head of a F-AAS device. 
 
Into the burner head, the sample is burned, and the temperature of the flame is optimized 
depending on the targeted element.  Into the flame occurs several reactions and processes. 
Firstly, the water molecules are evaporated and therefore removed from the sample 
(Lebedev, 2013). Then, the organic and inorganic dehydrated complexes are degraded into 
gaseous atomic ground states. In the hotter parts of the flame occur the absorption of photons 
by the ground state gaseous atoms that due to this absorption get excited.  
To excite the atoms, it is needed a light source that has to be pure to avoid excessive 
instrumental noise. Usually, as light source it is used a hollow cathode lamp that is specific 
for each element analysed and a double-beam technology. This technology consists in the 
splitting of the light beam into two paths, one of them do not passes through the sample and 
therefore is used to measure the interferences caused by lamp intensity fluctuations and other 
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sources not connected to the sample. The other beam is used to measure the actual radiation 
that interacts with the sample. As the lamp is specific for the element to analyse (only emits 
light in the wavelength that the element to analyse absorb) only the atoms of this element 
are going to absorb radiation and excite. This excitation results in a reduction in the intensity 
of radiation leaving the sample cell. This wicked radiation intensity is reflected by a series 
of mirrors into the monochromator and finally, the wavelength at which the element absorb 
is focused and amplified through the photomultiplier and the signal processed by the 
computer (Dimitrov Dakashev et al., 2012). A representation of the F-AAS is presented in 
Figure 18 for the better idealization of the process described above. 
 
Figure 18: Scheme of the setup of a typical F-AAS device. 
 
This technique was applied in many investigations reported by numerous articles. One 
example is an article that reported the used of flame atomic absorption spectroscopy to 
develop a method to rapid quantitative analysis of magnesium stearate in pharmaceutical 
powders and solid dosage forms (Sugisawa et al., 2009).  
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2. GRAPHITE FURNACE ATOMIC ABSORPTION SPECTROSCOPY 
In the past it was called as flameless atomic absorption (FAA) however, nowadays it is 
officially designated as electrothermal atomic absorption spectrometry (ET-AAS) by the 
IUPAC (International Union of Pure and Applied Chemistry) but is usually referred to as 
graphite furnace atomic absorption spectrometry or GF-AAS. 
This analytical technique (Figure 19) has a graphite tube of about 2.5 to 3 cm long and 
4 to 6 mm of inside diameter and it is composed of graphite with a pyropgraphite coating 
that is quite impermeable. This tube has a circular opening in the centre of approximately 1 
to 2 mm of diameter used to introduce the sample. 
 
Figure 19: 3D schematic representation of a graphite furnace tube. 
 
Usually, the sample volume used is 10 to 20 µL, but the graphite furnace has the capacity 
to hold an aliquot up to 50 µL. Then, the graphite furnace tube is placed inside the graphite 
chamber and subjected to a pre-programmed progressive heating. This heating program has 
four phases (Figure 20) and the temperatures dependent on the element analysed. During 
this process, the chamber is protected from the surrounding atmosphere through an Ar 
(Argon) flow around the furnace to prevent oxidation processes that would affect the 
quantification.  
 
Figure 20: Schematic representation of the four phases of the heating program of a 
GF-AAS in function of time. 
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The first step of the heating program is the drying one, in which the solvent is smoothly 
evaporated so that no sample projections occur to increase precision. Then, in pyrolysis the 
matrix components are mineralized. This step should be carried at the highest temperature 
possible without losing analyte. 
The next step is atomization, where is produced an atomic vapour that must be obtained 
at the lowest temperature possible that maximizes the atomization of the element analysed 
to obtain maximum sensitivity. Finally, in the last step, a flow of inert gas flow passes 
through the graphite chamber to eliminate matrix vapours (Inczédy et al., 1998). 
Also, during the heating process, a light source passes through the tube and at the end of 
the circuit a detector measures the analyte absorbance signal during the whole process. At 
that point, through a Beer–Lambert’s law, the absorbance signal is related to the element 
concentration. It is important to highlight that the light source is different depending on the 
element analysed as it is wanted the maximum absorption of the lamp radiation by the 
element so that the measurements can be accurate. 
This technique present detection limits in the order of low parts per billion or low ρg/L 
range and therefore is still currently one of the most sensitive techniques for elemental 
analysis. The fact that it is capable of analysing elements in sample micro amounts with 
complex matrices combining with the relatively low running cots made GF-AAS a very 
attractive option when a single element needs to be analysed, the sample volume available 
is low or the sample matrix is complex (Holcombe and Borges, 2010). 
One example that clearly illustrates what has been said is an article where is developed 
a graphite furnace atomic absorption spectroscopy method for the analysis of palladium (Pd) 
content in bulk pharmaceutical drugs. The results reported are all in low parts per billion as 
the lowest value is 2 ppb (part per billion) (Jia et al., 2001). 
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3. INDUCTIVELY COUPLED PLASMA - ATOMIC EMISSION 
SPECTROSCOPY 
Inductively coupled plasma-atomic emission spectrometry (ICP-AES) also known as 
inductively coupled plasma-optical emission spectrometry (ICP-OES) was first 
commercialized in the mid-1970s and quickly became one of the election techniques for the 
determination of elements with low abundance in a wide range of samples types.  
As schematized in Figure 21, the elements are aspirated into the spray chamber where 
the sample is converted into an aerosol (as explained with more detail in topic 4.1 of 
CHAPTER II).  Then, the aerosol is conducted into the plasma where occurs the sample 
atomization. Due to the energy provided by the plasma high temperatures, the molecules are 
degraded into atoms. However, as the plasma temperature is so high, the energy that it 
provides also excites the atoms. When the excited atoms reach a colder part of the plasma, 
they emit the energy and return to the ground state and is this emission that a diffraction 
grating (placed near the plasma) resolves into its component radiation for the measurement 
of light intensity by the photomultiplier tube. In other words, the light emitted by the atoms 
when they return to the ground state is converted to an electrical signal to be quantitatively 
measured. 
 
Figure 21: Scheme of a typical inductively coupled plasma-optical emission 
spectrometry system. 
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Since the first sold device, ICP has undergone a tremendous evolution both in the 
evaluation and understanding of the equipment with numerous studies on the system 
mechanisms and characterization and on the instrumentation level: the replacement of 
photomultiplier tubes by charge transfer devices for multielement determination, rotating the 
ICP through 90° in order to improve the detection limits and various sample introduction 
systems such as laser ablation and electrothermal vaporization (ETV) for solid sampling. 
ICP-OES analysis always involves sample preparation (Sneddon et al., 2006) and the 
use of calibration curves obtained through the analysis of standard samples (Dean, 2005; 
Hill, 2006; Nölte, 2003b; Thomas, 2004). The use of ICP-OES for elemental analysis has 
been increasing and one example of the usefulness of this technique is the article that reports 
the development of a slurry introduction method for multi-element analysis of antibiotics by 
inductively coupled plasma atomic emission spectrometry using various types of spray 
chamber and nebulizer configurations. This technique could quantify elemental impurities 
present in the antibiotics down to the μg/g level (Zachariadis and Michos, 2007). 
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1. VALIDATION OF THE QUANTIFICATION METHOD FOR CR 
1.1. SPECIFICITY AND SELECTIVITY 
1.1.1. RECOVERY TESTS – MATRIX INTERFERENCES 
 
Figure 22: Control chart of Cr recovery tests in Brufen samples. 
 
Figure 23: Control chart of Cr recovery tests in Maalox samples. 
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1.2. LIMITS OF DETECTION AND QUANTIFICATION 
 
Figure 24: Verification chart of the values obtained after digestion of blank solutions 
concerning the determination of Cr and respective limit of detection (LOD) and limit of 
quantification (LOQ). 
 
Figure 25: Verification chart of the blanks solution values concerning the 
determination of Cr and respective limit of detection (LOD) and limit of quantification 
(LOQ). 
 
Table 20: Equations and respective values of limit of detection (LOD) and limit of 
quantification (LOQ) for digestion blank and blank solutions regarding Cr quantification 
Equation Digested blank Blank solutions 
𝑳𝑶𝑫 = 𝟑𝒔𝟎 2,53E-01µg/L 1,22E+00 µg/L 
𝑳𝑶𝑸 = 𝟏𝟎𝒔𝟎 7,68E-01µg/L 3,70E+00 µg/L 
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1.3. WORKING RANGE 
Table 21:  Parameters and respective values for the construction of the linear 
calibration function for Cr. 
Standard 
Conc. 
(µg/L) 
Signal 
(cps) 
si si2 si-2 
P 0,0 0,000 1175 0,00 5,00E-07 2,00E+06 
P 0,5 0,500 1,67E+03 0,01 3,20E-05 3,12E+04 
P 2,0 2,00 3,10E+03 0,02 4,80E-04 2,08E+03 
P 10 10,0 1,09E+04 0,06 4,14E-03 2,42E+02 
P 50 50,0 5,06E+04 0,33 1,10E-01 9,09E+00 
P 100 100 9,92E+04 0,08 1,10E-01 9,09E+00 
Sum 1,63E+02 1,67E+05 5,08E-01 2,25E-01 2,03E+06 
Mean 2,71E+01 2,78E+04 8,46E-02 3,74E-02 3,39E+05 
 
Table 22: Parameters and respective values for the construction of the linear 
calibration function for Cr - Continuation. 
Standard 
Conc. 
(µg/L) 
wi wi*xi wi*yi wi*xi*yi wi*xi2 
P 0,0 0,000 5,90E+00 0,00E+00 6,93E+03 0,00E+00 0,00E+00 
P 0,5 0,500 9,22E-02 4,61E-02 1,54E+02 7,71E+01 2,30E-02 
P 2,0 2,00 6,14E-03 1,23E-02 1,91E+01 3,81E+01 2,46E-02 
P 10 10,0 7,13E-04 7,13E-03 7,75E+00 7,75E+01 7,13E-02 
P 50 50,0 2,68E-05 1,34E-03 1,36E+00 6,79E+01 6,71E-02 
P 100 100 4,24E-04 4,24E-02 4,21E+01 4,21E+03 4,24E+00 
Sum 1,63E+02 6,00E+00 1,09E-01 7,16E+03 4,47E+03 4,42E+00 
Mean 2,71E+01 1,00E+00 1,82E-02 1,19E+03 7,44E+02 7,37E-01 
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Table 23: Calibration standards residual error value (%) for Cr. 
Standard 
Conc. 
(µg/L) 
Calculated 
Signal 
(cps) 
Residual 
Residual 
Error 
(%) 
Calculated 
[Cr] 
(µg/L) 
|Relative 
Error| 
(%) 
P 0,0 0,000 1,18E+03 -7,57E-02 -0,010 -7,72E-05 - 
P 0,5 0,500 1,67E+03 7,62E+00 0,460 5,08E-01 1,55 
P 2,0 2,00 3,14E+03 -3,23E+01 -1,04 1,97E+00 1,65 
P 10 10,0 1,10E+04 -9,92E+01 -0,910 9,90E+00 1,01 
P 50 50,0 5,02E+04 4,04E+02 0,800 5,04E+01 0,820 
P 100 100 9,92E+04 4,94E+00 0,000 1,00E+02 0,010 
 
 
Figure 26: Experimental data collected and respective linear calibration function for 
Cr. 
 
Table 24: Weighted calibration function parameters for Cr. 
bw aw  r 
3,05E+02 1,75E+02 0,999997 
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Figure 27: Residual error (%) for Cr quantification. 
 
1.4. TRUENESS, PRECISION AND UNCERTAINTY 
1.4.1. TRUENESS 
 
Figure 28: Control chart of bias (%) for Cr quantification. 
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1.4.2. PRECISION 
1.4.2.1. SAMPLE VARIATION COEFFICIENT (RELATIVE STANDARD 
DEVIATION) 
 
Figure 29: Control chart of the relative standard deviation (RSD, %) for Cr 
quantification in Brufen. 
 
Figure 30: Control chart of the relative standard deviation (RSD, %) for Cr 
quantification in Maalox. 
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1.4.2.2. REPEATABILITY VARIATION COEFFICIENT 
Table 25: Estimated CVr (%) and HORRATr values for Cr quantification in Brufen. 
 Nº of 
readings 
CVr (%) HORRATr 
Day 1 8 11,8 5,8 
Day 2 7 5,2 2,6 
Day 3 8 19,6 10,4 
 
Table 26: Estimated CVr (%) and HORRATr values for Cr quantification in Maalox. 
 Nº of 
readings 
CVr (%) HORRATr 
Day 1 7 5,1 2,8 
Day 2 8 4,1 2,3 
Day 3 8 3,3 1,8 
 
1.4.2.3. INTERMEDIATE  
Table 27: Estimated values of CVSI (%) and HORRATSI for Cr quantification in 
Brufen and Maalox. 
Pharmaceutical 
Drug 
CVSI (%) p n HORRATSI 
Brufen 29,2 3 22 15,0 
Maalox 5,9 3 22 3,2 
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2. VALIDATION OF THE QUANTIFICATION METHOD FOR CU 
2.1. SPECIFICITY AND SELECTIVITY 
2.1.1. RECOVERY TESTS – MATRIX INTERFERENCES 
 
Figure 31: Control chart of Cu recovery tests in Maalox samples. 
 
2.2. LIMITS OF DETECTION AND QUANTIFICATION 
 
Figure 32: Verification chart of the values obtained after digestion of blank solutions 
concerning the determination of Cu and respective limit of detection (LOD) and limit of 
quantification (LOQ). 
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Figure 33: Verification chart of the blanks solution values concerning the 
determination of Cu and respective limit of detection (LOD) and limit of quantification 
(LOQ). 
 
Table 28: Equations and respective values of limit of detection (LOD) and limit of 
quantification (LOQ) for digestion blank and blank solutions regarding Cu quantification 
Equation Digested blank Blank solutions 
𝑳𝑶𝑫 = 𝟑𝒔𝟎 9,22E-01µg/L 1,11E+00 µg/L 
𝑳𝑶𝑸 = 𝟏𝟎𝒔𝟎 2,79E+00 µg/L 3,37E+00 µg/L 
 
2.3. WORKING RANGE 
Table 29:  Parameters and respective values for the construction of the linear 
calibration function for Cu. 
Standard 
Conc. 
(µg/L) 
Signal 
(cps) 
si si2 si-2 
P 0,0 0,000 3,70E+02 0,11 1,26E-02 7,91E+01 
P 2,0 2,00 6,73E+02 0,06 3,28E-03 3,05E+02 
P 10 10,0 2,07E+03 0,03 1,10E-03 9,05E+02 
P 50 50,0 9,04E+03 0,33 1,09E-01 9,21E+00 
P 100 100 1,76E+04 0,25 6,20E-02 1,61E+01 
Sum 1,62E+02 2,98E+04 7,81E-01 1,88E-01 1,31E+03 
Mean 3,24E+01 5,96E+03 1,56E-01 3,75E-02 2,63E+02 
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Table 30: Parameters and respective values for the construction of the linear 
calibration function for Cu - Continuation. 
Standard 
Conc. 
(µg/L) 
wi wi*xi wi*yi wi*xi*yi wi*xi2 
P 0,0 0,000 3,01E-01 0,00E+00 1,11E+02 0,00E+00 0,00E+00 
P 2,0 2,00 1,16E+00 2,32E+00 7,80E+02 1,56E+03 4,64E+00 
P 10 10,0 3,44E+00 3,44E+01 7,14E+03 7,14E+04 3,44E+02 
P 50 50,0 3,50E-02 1,75E+00 3,17E+02 1,58E+04 8,76E+01 
P 100 100 6,14E-02 6,14E+00 1,08E+03 1,08E+05 6,14E+02 
Sum 1,62E+02 5,00E+00 4,46E+01 9,43E+03 1,97E+05 1,05E+03 
Mean 3,24E+01 1,00E+00 8,93E+00 1,89E+03 3,94E+04 2,10E+02 
 
Table 31: Calibration standards residual error value (%) for Cu. 
Standard 
Conc. 
(µg/L) 
Calculated 
Signal (cps) 
Residual 
Residual 
Error (%) 
Calculated 
[Mn] 
(µg/L) 
|Relative 
Error| 
(%) 
P 0,0 0,000 3,41E+02 2,94E+01 7,95 1,70E-01 - 
P 2,0 2,00 6,87E+02 -1,39E+01 -2,06 1,92E+00 4,00 
P 10 10,0 2,07E+03 1,99E+00 0,10 1,00E+01 0,11 
P 50 50,0 9,00E+03 4,22E+01 0,47 5,02E+01 0,49 
P 100 100 1,77E+04 -1,80E+01 -0,10 9,99E+01 0,10 
100 
 
 
Figure 34: Experimental data collected and respective linear calibration function for 
Cu. 
 
Table 32: Weighted calibration function parameters for Cu. 
bw aw  r 
3,41E+02 1,73E+02 0,999985 
 
 
Figure 35: Residual error (%) for Cu quantification. 
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2.4. TRUENESS, PRECISION AND UNCERTAINTY 
2.4.1. TRUENESS 
 
Figure 36: Control chart of bias (%) for Cu quantification. 
 
2.4.2. PRECISION 
2.4.2.1. SAMPLE VARIATION COEFFICIENT (RELATIVE 
STANDARD DEVIATION) 
 
Figure 37: Control chart of the relative standard deviation (RSD, %) for Cu 
quantification in Maalox. 
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2.4.2.2. REPEATABILITY VARIATION COEFFICIENT 
Table 33: Estimated CVr (%) and HORRATr values for Cu quantification in Maalox. 
 Nº of 
readings 
CVr (%) HORRATr 
Day 1 8 15,7 6,8 
Day 2 8 8,1 3,4 
Day 3 8 7,8 3,2 
 
2.4.2.3. INTERMEDIATE PRECISION 
Table 34: Estimated values of CVSI (%) and HORRATSI for Cu quantification in 
Maalox. 
Pharmaceutical 
Drug 
CVSI (%) p n HORRATSI 
Maalox 18,1 3 23 7,61 
 
